{
    "id": "64krvocv6nfnrje5arc7zivn2pz5xtmf",
    "title": "Using human genomic variation for individualisation of drug treatment",
    "info": {
        "author": [
            "Munir Pirmohamed, Department of Molecular and Clinical Pharmacology, University of Liverpool"
        ],
        "published": "July 21, 2014",
        "recorded": "May 2014",
        "category": [
            "Top->Medicine"
        ]
    },
    "url": "http://videolectures.net/mdo2014_pirmohamed_drug_treatment/",
    "segmentation": [
        [
            "It's great to be here and thank you for the invitation to come to the MDO.",
            "So I'm a clinician and I am going to give you a very translational talk.",
            "I will try to disperse that with some mechanisms.",
            "So.",
            "I was given this particular title, so in order to fulfill this particular title, I really need to take you through what happens in clinical practice and then tell you about the difficulties of implementing biomarkers into clinical practice.",
            "Oops, not working.",
            "So."
        ],
        [
            "2.",
            "If you talk to physicians, they will tell you that they've been personalizing treatments for centuries, and in a way, when I see a patient, I use the best evidence that's available to me, usually from randomized control trials.",
            "Which are population based studies really to treat the patient was in front of me in the surgery.",
            "So I'm going from population level evidence to try to extrapolate that to the individual, and that's always difficult.",
            "This has proven benefits from a population perspective, but it's less difficult.",
            "It's more difficult to predict at an individual level.",
            "We can't predict whether an individual get side effect and how severe the side effect will be, and we can't predict whether the patient will improve in response to the drug that I give to them.",
            "And that creates problems and we've known."
        ],
        [
            "About the fact that there is variability in responses to drugs and this is taken from the Physicians desk reference and it basically shows you what their efficacy rate is and this is a slide that almost everybody uses in this area and talking about pharmacogenetics and so on.",
            "And Alan Roses who was previous GSK vice president, was very honest when he gave a talk in London at the DIA Conference.",
            "Instead, the vast majority of drugs more than 90%.",
            "Only working 30 to 50% of people and a journalist was in the audience and you can see ended up on the front page of a newspaper in the UK the next day.",
            "He had to go in front of the chief executive at GSK to tell them why the share price has gone down.",
            "So you have to be careful what you say, so I hope they know journalists."
        ],
        [
            "The other problem is that you do get adverse drug reactions, and we've done some of the biggest studies in the world, and there are other studies in the United States as well, and at the moment in the United Kingdom, if you will look at the whole bed base in the whole healthcare system, 8000 beds are occupied for patients with adverse drug reactions, not all of them are related to genetics.",
            "Some of them are related to poor prescribing and so on.",
            "But nevertheless there are severe reactions such as this toxic epidermal necrolysis.",
            "Which are related to genetics an if we had some genetic input into the way we look after patients, we could reduce some of them and it's been estimated that we could probably reduce about 30% of adverse drug reactions considering the costs.",
            "the UK healthcare system by 1 billion pounds a year, then that's still a big saving by incorporating genetics."
        ],
        [
            "So this is my concept of where pharmacogenetics fits in into the whole structure of personalized medicine.",
            "You know that people talk about personalized medicine, to talk about precision medicine.",
            "They talk about stratified medicine, and at the moment what we do when we treat patients is really based on definitions of disease which span back to the 19th and 20th century where we take a disease is a phenotypic definition.",
            "What symptoms the patient has was science.",
            "The patient has what the histologies of their disease and and that's the current standard.",
            "But as we learn more about disease."
        ],
        [
            "And we learn about the molecular subtypes of disease.",
            "We're going to be able to stratify disease into different strata, so inflammatory bowel disease won't be one disease.",
            "It will be many different strata of disease, and that disease stratification is going to be very important in terms of determining which treatment a patient needs.",
            "But even when you look at different disease strata.",
            "And you start to give therapies within those different disease strata then."
        ],
        [
            "You will still going to have variability in the way our drugs work in that disease, and this is where pharmacogenomics comes in to be able to define how the drug is handled in their individual in that disease stratum, as well as how it's it causes adverse effects but."
        ],
        [
            "Mostly patients are all different.",
            "They drink, they smoke, they eat differently.",
            "They have different weights, etc.",
            "And we need to take that into account when we treat patients as well, and only when you can take all these factors into account.",
            "Environmental drug variability, molecular definition, etc.",
            "That you can really practice personalized medicine, so it's a tough ask to be able to take all these into account and in a way for those systems biologists here, you've got a multi scale model.",
            "Yeah, and you'll be able to need to fulfill a multiscale model to be able to really come out with the key decisions as to which drug is best in which patient."
        ],
        [
            "So when people look at pharmacogenomic variation in drug response, I don't need to obviously label this point with this audience.",
            "You can generally divide it into pharmacokinetics, adme or pharmacodynamics and so on, and the different drug targets on the slide.",
            "But what you do have in many cases is that you have both pharmacokinetic determines and pharmacodynamic risk determinants.",
            "And I'll come back to that later on.",
            "But if you look at the literature we've mostly concentrated on pharmacokinetics in terms of pharmacogenomics, but maybe pharmacodynamic targets are much more important in terms of determining response, but we need to be able to look at that together."
        ],
        [
            "So.",
            "When you look at human genomic variation individualization drug treatment, there are examples when it works beautifully and I'm going to go through that.",
            "One example of that in an area that we work in, which is HLA."
        ],
        [
            "An HLA is the perhaps most polymorphic region, or the MHC is the most polymorphic region of the human genome is on the short arm of chromosome 6, and there are three different regions of chromosomes HLA that is class one ABC Class 2 DRD CDP and in between class One and Class 2 is the Class 3 region where you have heat shock protein, tumor necrosis factor Alpha, and Micah.",
            "And and these this particular region is in important in protecting people from infectious diseases.",
            "That's how we Mount an immune response to the virus is that we get orders of bacteria that were infected with also important in autoimmune diseases.",
            "But it's also important in immune mediated adverse drug reactions such as the picture I showed you before of toxic, epidermal necrolysis and if you look at the literature since 2001 since the beginning of this century, they've been 23.",
            "Different HLA associations which have been associated with the HLA genes and some most of them are at a genomewide significant level, so that's an enormous amount of work that's been done in this area and very very important findings for 23 different associations with different drugs with adverse drug reactions affecting not only the skin but also liver.",
            "And you'll hear about liver injury later on today."
        ],
        [
            "And perhaps the best example of that is with the drug abacavir, which everybody knows about, but it's important to go through how well it went into the literature, but also some other benefits it has so back of ear causes this hypersensitivity reaction.",
            "Which is a skin rash, generalized, systemic manifestations, etc and work undertaken in Australia and then in North America and then also by our so."
        ],
        [
            "Else was able to show very strong Association with HLA B Star 5701.",
            "Now to get it into clinical practice you need to undergo various different steps and one of those is to show that it is cost effective."
        ],
        [
            "To be able to incorporate that into clinical system.",
            "So we ask the simple question, would it be cost effective to introduce H 57 one typing into the UK National Health Service and would that save money for the UK National Health Service?",
            "And we understood we constructed various models, economic models and so on.",
            "And we came out with a conclusion there.",
            "Yes, it would be cost effective and this paper was published in Pharmaco Genetics in 2004 and by 2006 every patient in the UK was getting 57.",
            "One test to prevent abacavir hypersensitivity.",
            "So two years in translation, which is a fantastic outcome and tells you that when it does work.",
            "It can work very well and really does make a difference.",
            "Ah."
        ],
        [
            "In fact, the net effect of there has been dramatic.",
            "So if you look at the frequency before testing, pre testing was 7% in Australia less than 1% in France went from 12% to 0% in the UK clinic in London went from 8% to 2% and the 2% was higher than it should have been because one patient was given the drug before they had the test result and that tells you the problem of the you need the test result quickly if you're going to prescribe a drug based on the test.",
            "You can't wait for two weeks to get a test result, so turn around time because important as part of the translation pathway."
        ],
        [
            "And this is what it's done in terms of usage of the drug.",
            "And this is only data till 2009.",
            "But this is what happened when we started introducing it in the UK and these are some of the red is the number of HLA tests which occurred in the UK.",
            "And if you look at Kivexa, which is abacavir before the test was introduced, the usage was very low.",
            "But you can see in parallel the Kivexa usage went up, while the usage of other drugs so just come over, and so on went down.",
            "So while people worry about the fact that if you're going to introduce testing, it's going to reduce the use of your drug, because people won't be bothered testing or will be too expensive.",
            "What you can actually showing here is that introducing a genetic test actually increased the use of the drug.",
            "Because the physicians became more confident using it and patients became more confident in taking the drug.",
            "So genetics was working for actually using the drug in clinical practice.",
            "Importantly, this particular genetic finding has also led to important mechanistic findings, and that's where something that we always always try to tend to ignore is that pharmacogenetic associations, even you can't put them into clinical practice, actually can give you a lot of information about mechanisms."
        ],
        [
            "And and a year or two ago, three papers came out almost simultaneously, one in nature, one in PNS and one in AIDS, which showed that the mechanism are potential mechanism.",
            "There are other mechanisms as well about how abacavir maybe binding to the 57 one and therefore inducing an immune reaction.",
            "And this is shown here."
        ],
        [
            "And this is the cleft MHC cleft for 57.",
            "One with the F Pocket we're back of his tour to bind.",
            "And normally when they serve in its resting state, there are peptides within the MHC cleft.",
            "But when patients with 57 one are exposed to abacavir, the abacavir goes and binds to this MHC cleft and displaces some of these peptides.",
            "And if you look at the peptides pet do peptide elution from this and look at some of the peptides, you start showing novel self peptides when the back of his present within the cleft.",
            "And these novel self peptides have isoleucine, leucine, occupying C terminal anchor proteins rather than the conventional peptides which are present.",
            "So water back of is doing is displacing the normal peptide compliment and a different peptide compliment is coming through.",
            "And then I'll turn it.",
            "Peptide complement is recognized as being foreign, and that induces an immune reaction and it's very neat hypothesis.",
            "It's only been proven in vitro, but nevertheless now it needs to be some further work needs to be done to be able to prove that.",
            "In vivo and if you look at closely related other types such as 5703, there's no change in peptide profile, so it's very very specific for 5701 and tells you about the specificity and define some ways of how drugs can interact with very specific, I mean acid molecules within very specific binding pockets within the MHC."
        ],
        [
            "Another example, how where it actually makes sense that genomic variation is important, and this is an example which is from."
        ],
        [
            "That's not our example.",
            "It's from the new Jenna Mattson published early this year and this is in a condition rare condition called peroxisomal nocturnal hemoglobin area in a normal red blood cell.",
            "What you have so you have G protein anchored proteins and these were such a CD55 CD.",
            "59 and when you have compliments such as C5 it binds to this proteins and you can prevent hemolysis.",
            "But if you haven't.",
            "Absence of this and this is somatic mutation is not.",
            "An acquired mutation is somatic mutation.",
            "You lose the ability to be able to bind these, purchase the surface compliment goes in and causes hemolysis.",
            "Not only do get hemolysis of red blood cells, but you get thrombosis and Sciences very severe disease process with nocturnal hemoglobin, nuria and these GPI anchored protein CD fifty five 7059 are absent because this somatic mutation.",
            "So there is a monoclonal antibody humanized monoclonal antibody called.",
            "Eckel is a map which binds to C5, inhibits an activation, but 3% of patients have a poor response.",
            "They don't respond to Equalism app."
        ],
        [
            "And so these investigators in Japan started looking at those 3% of patients and found that there is a missense mutation identified the C5 complement gene.",
            "And when they did some in vitro studies, they were able to show that while Equalism is able to block C5 media team olisis in non mutant red blood cells, it can't do that in the those carrying the variant.",
            "And you can see those patients with a Japanese patient with poor response had this Miss sense here and the Argentinian patient had poor response.",
            "As well, so this is something that actually makes sense because you know, it's a drug target and you can actually show where there's difference.",
            "You may get differences in binding to something which is very specific, such as Eckel is a map."
        ],
        [
            "But so those are the kind of gold standards.",
            "If you like.",
            "Usually it's much more difficult, and I'm going to take you through some of the difficulties.",
            "And it's been an given, the audience, and so on.",
            "I'm going to concentrate particularly hopeful."
        ],
        [
            "On more on pharmacokinetics and if you look at the sources of variation and there are an increasing number of examples of pharmacodynamic genetic variations which are being used in clinical practice, such as the B RAF mutation, which is now found in malignant Melanoma in thyroid cancer as well as in hairy cell leukemia, and you have drugs such as very rough and which can interact with that be reputation and cause regression of that cancer, at least for a short time.",
            "But pharmacokinetic variation has been much more difficult to implement to clinical practice.",
            "Perhaps the most successful has been therapure in methyltransferase, which deficiency causes bone marrow suppression.",
            "With six mercaptopurine azathioprine, that's probably the most successful farm kinetic variation implementing clinical practice.",
            "But I think it is important to note that PK and PD factors work together, and I think taking account about those can improve prediction and warfrin is a specific example where we worked on and they've been two trials published recently with which created a lot of confusion.",
            "So I'm going to take you through the Warframe story and tell you about possible potential reasons why there's been differences between two different trials recently.",
            "Trying to relate it to pharmacology and P-450 particularly C9.",
            "So what?"
        ],
        [
            "Is a very widely used vitamin K antagonist at 1% of the UK population.",
            "Use it.",
            "The problem with warfrin as you know is that you can't predict the doses of 44 variability in dosage.",
            "And if you look at any epidemiological studies, you find that Warren is in the top three of drugs which cause hospital admission because of bleeding, such as in this patient, and so on.",
            "So despite the fact that warframe's been around for 60 years and we are still having difficulty in using it and it still causes a lot of problems.",
            "So the question that everybody's been looking at is can you predict dose with Warframe?"
        ],
        [
            "And you really need to go to the metabolism of offering and the way Warren acts to be able to try to define what may be important so often is administered as at arness, warfare enantiomers and the S enantiomer is the more active enantiomer, and cytochrome P452C9 is responsible for the metabolism of S warfrin.",
            "WARFRIN binds to vitamin K booksellers complex, inhibiting it and therefore preventing the formation of activated clotting factors 279 and 10.",
            "And So what we have is a combination of pharmacokinetic factors as well as pharmacodynamic factors which actually then lead to the overall effect of Warframe which is anticoagulation.",
            "And we measure that using the international normalized ratio and try to keep it between two and three in most indications so work has been going on."
        ],
        [
            "To identify genetic factors in this and this by many different groups all over the world, including ourselves.",
            "And I'll come back to that in a minute.",
            "So one of the problems is how much of this of problems that you get with warfrin is related to an ion are which is a biomarker that we use now.",
            "You can see that the response is quite different in different individuals in terms of dose variation, and if you get a high INR your rate of bleeding goes up.",
            "So if you're above 4.1 rate of bleeding is 99.26 compared to somebody who's got a much lower INR.",
            "But if you actually look at the literature.",
            "Only 50% of bleeds that occur with warfrin, which is what we're trying to prevent, occur with an INR greater than two point 550% occur at levels below this.",
            "So if you're going to try to implement.",
            "War friend dose prediction and base it on Ion.",
            "Are you only going to succeed 50% of the time with 50% of the time you're not going to succeed anyway, so your success rate is already being cut down by 50%.",
            "And that makes it difficult to then implement that into clinical practice.",
            "So."
        ],
        [
            "Work which is undertaken in many different areas of the world, including by ourselves, has shown that there are environmental factors, clinical factors as well as genetic factors important in determining what the dose of warfarin is that you require every day.",
            "So there are the clinical factors such as age, height and weight.",
            "10 to 20% is what they account for in terms of dose variation, and that's been known since the 1970s and 1980s.",
            "Then there are drug interactions and I'm your drone.",
            "Particularly important here, about 5 to 10% in terms of accounting for dose variation.",
            "Then there are genetic factors and genetic factors.",
            "Overall account for greater part of what determines their or anticoagulation control.",
            "So cytochrome P452C9, particularly the start and start three alleles account for 15% of those variation and vitamin K project complex accounts for about 25% of the dose variation.",
            "And so if you look at the literature."
        ],
        [
            "And look at all the data on Warfrin Warfrin and the two C9 V Coc.",
            "One genetics has been replicated almost everywhere in every population, and so this is one of the most highly replicated genotype phenotype associations in the world.",
            "And so you know which which is important, because as you know, with many different genetic associations we have difficulties in replicating."
        ],
        [
            "And so are there any other genetic factors?",
            "This is data from our unpublished G was that we had taken in 714 patients and what we're looking at is war for the mean weekly dose.",
            "For those of you who do not know exactly what all this stands for, then on this you have each of the individual chromosomes up to chromosome 22 and then on the Y axis is a minus log 10 P value and this is called a Manhattan plot.",
            "But what you find is that there are only two peaks coming up here.",
            "You know one for cytochrome P42C9 in Crimson 10, another one for vitamin K Pixel is complex and chromosome 16.",
            "So despite the fact that you know we looked at so many different million snips across this, we couldn't find anything in literature.",
            "People have been able to find anything there is cytochrome P-450 or 4F2.",
            "We only accounts .5 to 1% of the dose variation.",
            "And that certainly didn't show up in our particular study.",
            "So based on that.",
            "Then one could say that we will need to develop algorithms and so on, and people have."
        ],
        [
            "Come together all around the world an and in the area of genetic Association studies and so on.",
            "It is important to have consortia working together and pulling data so that you can get better power in terms of what you do.",
            "So we published this as part of the International War Frank Genetic Consortium.",
            "In the new General medicine and developed dosing algorithms dosing algorithms which contain the genetic data as well as dosing algorithms which contain clinical data and this has been the basis of what the trials.",
            "That will be undertaken.",
            "Have utilized these kind of algorithms."
        ],
        [
            "So there have been several trials going on around the world and and the the trial in the EU, which I was involved in, was been sponsored by the European Commission and the trial was being undertaken in the United Kingdom and in Sweden because these two countries use Warframe, but there were two other trials.",
            "One was unfair pro Kumon and the other one was an Acer camera which were being undertaken.",
            "Other parts of Europe where those particular vitamin can techniques are being used.",
            "And and the design was quite simple, while relatively simple in that you patient was recruited to the study.",
            "They were randomized to receive either genotype guided care or standard care, and So what happens in the patient is randomized to genotype guided care is that we take a small amount of blood about one mil.",
            "We put this into the point of care test.",
            "Here we are working with a company called LG See in London who are a partner in this U grant.",
            "And this particular point of care platform gives you results on three alleles.",
            "That is start to start Re and Vico C1 in 2 hours and you put the results of the Geno types into computer dosing algorithm, which then tells you what the dose should be for the first three days for the genotype guided arm and what we then did was to compare it to standard care standard care at the moment in the UK and Sweden is that you give a loading dose at the beginning.",
            "A standard dose 10 five 5 is what we used and then we compare the 10 five 5 milligrams versus the individualized dose and the important thing was at the same time we could actually test the utility of a point of care test."
        ],
        [
            "And so we published this in the New England Journal of Medicine just before Christmas, about December last year.",
            "And what we found is shown on this particular slide with two different kinds of analysis, something called an intention to treat analysis in the per protocol analysis.",
            "And basically if you look at the control arm, first of all, what we got was the time in therapeutic range.",
            "And this was the primary outcome measure.",
            "This is a percentage of time in therapeutic range.",
            "During 12 weeks.",
            "Follow up after starting Warfar in therapy and 63% percent ETR is very good for three months.",
            "It's kind of gold standard.",
            "You rarely get above that with normal Warframe care, but despite the fact that we were had a very good TTR in the control arm, we actually managed to get better one in the Geno, type them and there's 7% difference between genotype and standard dosing with the P value, which is highly significant."
        ],
        [
            "And let me just show you in more detail what happened between the different groups and the genotype guided group.",
            "Here is in blue and the control group is in red and if you look at the international normalized ratio and we try to aim between 2:00 and 3:00 and you can see in the control group you were getting higher values, you were getting overshoot above 3 at the beginning based on the initiation that we did and then in the genotype guided group it was actually better you weren't getting the overshoot and it was much better control.",
            "Overall remaining about 2.5 throughout, while the control group overshot and then with monitoring, eventually came down to the kind of 2.5 min level.",
            "And if you look at time in therapeutic range, the control group had worst time in therapeutic range throughout three months.",
            "But separation between the genotype guided group and Control Group was occurring about 10 to 15 days.",
            "So within 10 to 15 days you can show a difference with this dosing regiment.",
            "That genotype dosing regimen was working better in terms of getting patients into the correct range."
        ],
        [
            "Now at the same time, in the same issue there was American trials published as well and that's called COAG and that showed no difference between genotyped and control arms.",
            "Now people say we need control trial randomized control trials to show how we can get biomarkers into clinical practice.",
            "But there were two controlled trials carried out with different designs were showing completely different results and clearly that is that has created a problem.",
            "It's created a lot of controversy.",
            "A lot of debate.",
            "Anne for example."
        ],
        [
            "Genome Web said two conflicting perspective randomized control trials.",
            "No different guidance to clinicians.",
            "There was a.",
            "There was an editorial associated with the two studies, or there were three studies published.",
            "I'll come back to the third one.",
            "There was a.",
            "The tutorial from Bruce Fury.",
            "And he said the conclusions of the three studies are similar.",
            "Now maybe he was reading a different trial than I was, but the trial that we had in EU pact versus the COAG had different results.",
            "One showed it worked once, showed it didn't work, and he said it was similar.",
            "So I don't think he could explain the reason, so he just decided to take the easy option."
        ],
        [
            "So let me show you why I think that there were different and this is my interpretation.",
            "Obviously people from COAG may have a different operation, so you can either be in a pessimist and you can say that your glass is half empty, or you can be optimised like I am says half full and you can really learn things from trials and you can actually learn about the pharmacology and how you put pharmacology into practice and how you integrate that with in genetics to see how you can actually make things work.",
            "And I'm going to I'm going to take you through."
        ],
        [
            "Pharmacological explanation of why there were differences.",
            "How can we explain the differences?"
        ],
        [
            "Well, the most important thing if you're going to do a trial which is complex, is that you've got to get the algorithms right.",
            "And algorithmics strategy between the two different studies was completely different.",
            "So if you look at you packed what we did was we used a loading dose algorithm.",
            "That is, we loaded at the beginning for the first 3 days and then we went on to kind of maintenance dose.",
            "Whereas in COAG there wasn't a loading dose, it was more maintenance dose.",
            "There was some increase dose on first date but it's based on the maintenance dose.",
            "They formed a five.",
            "We use a different algorithm which is decision algorithm But so did COAG.",
            "And then after from day six, up to three months, we used normal anticoagulant clinics in the UK and Sweden where they use computerized dosing software to be able to dose individual patients in COAG, only followed patients for one month, and it was a protocol driven but really the biggest difference was in day one to three, which in loading this algorithm versus the maintenance dose algorithm.",
            "Now how can you explain that pharmacologically?",
            "Why is that important?"
        ],
        [
            "Well, if you look at S warfrin elimination, half life events warrant is 18 to 35 hours.",
            "So there is some variation.",
            "So the time to steady state if you starting a new patient removed from these were all new starters and warfrin will be 92175 hours.",
            "So, but if you give a loading dose, you can shorten that.",
            "Steady state.",
            "OK, but if you look at the dosing algorithms on day four where you have and I and I, you have to measure and then check what the next dose is most patients in if you give them maintenance dose will not reach steady state, so there may not be much change in INR and therefore on day four what you were doing was actually comparing the same different arms rather than one arm where the INR may have changed another arm where the right now didn't change.",
            "So what I don't know is we know from our particular trial what proportion of patients had a change in INR by default, but what I don't know is how many in COAG had a change in INR by day four, because the algorithm stretches it that they used and so the importance of the dough sing the loading dose initiation dose becomes apparent because of the half life of warfare in which which is much greater, which which is very long."
        ],
        [
            "Also, in COAG the algorithm did not include CYP 2C9 on day one and the reason they said that I was dosing patients with start to and start three variants are lower doses during the first day of therapy may not lead to improvements.",
            "Antika regulation could lead to worse antika regulation, but that statement is based on the maintenance dose.",
            "That is maintenance dose that if you're patient, if you have been stable for many months, you've got a maintenance dose and and really it may not make much difference in that stage."
        ],
        [
            "However, when we undertook a perspective course study in new starters warfrin, we found that site of Snips in CYP 2C9, but not Vico C One who associate with time to stable those time to therapeutic INR and ion are greater than four.",
            "So in the algorithm that we use in EU packed, we incorporated start to and start three within the algorithm on day one.",
            "But Coag didn't, and COAG only started using cytochrome P452C9 polymorphisms on day 2.",
            "Day 3 on after that and that, I think may have led to differences between the two trials."
        ],
        [
            "There was also a lot of ethnic heterogeneity in COAG, whereas in you packed it was mostly Caucasians.",
            "90 centers in Caucasians in Coag 67% white, 27% black and 6% Hispanic.",
            "And in COAG the Blacks did worse in the genotyped arm in then in the clinical group and there was 8% difference between the two groups and what you so you can see here is this 22C9 polymorphism frequency.",
            "So start to start.",
            "Three are relatively common in Caucasians, but really absent in African Americans.",
            "But there's African Americans have different snip star rate Star 11 which are not found in Caucasians and So what this tells you is that if you are going to take.",
            "This can algorithmics strategy.",
            "You need to use ethnic specific algorithms to dose patients as well, and this is where the basic biology and knowledge of before 15 variation in different ethnic groups becomes very important."
        ],
        [
            "Now the other thing to note was that we had different control arms and this has been used as an explanation for why things were different between the two trials.",
            "In IUPAC, we used a fixed dosing regiment which reflects current clinical cares said in Sweden in the UK.",
            "In COAG, a clinical algorithm was used which included all factors apart from genetics, so this was interpreted as genetics does not add anything over and above the clinical factors and some people after the trial have actually advocated the use of clinical algorithm.",
            "The important thing to note here is a clinical algorithm is never been tested in randomized control trial before, so if you start incorporating clinical algorithms into clinical practice based on this trial when it's never been tested on his own compared to standard care, then you are accepting a clinical algorithm at a lower evidential standard compared to genetics.",
            "And this again reflects the genetic exceptionalism that sometimes occurs and I'll come back to that.",
            "However, despite the fact that we"
        ],
        [
            "Standard dosing and they had a clinical algorithm.",
            "You have to look at the TTR between the two trials so you can see in COAG.",
            "In the genotype Tom Percent ETR, four weeks was 45% in EU.",
            "Pact is much higher at 54% in the control arm.",
            "It was similar at 4 weeks and 12 weeks.",
            "All the data have in the public domain is that it was 51% in both arms, but it's unlikely to be different between the genotype and control arms.",
            "Yet if you look at EU pact, the TTR 67.4% in the genotype time and 63% in the control arm.",
            "So what we were getting was a TTR which was much better even in the control arm compared to the genotype time at three events in COAG.",
            "So despite the fact the user click algorithm their overall anticoagulation care was worse than that seen in EU pact."
        ],
        [
            "And in fact, what you find is that we did the studies in two different countries, which are Sweden and UK.",
            "And Sweden is number one in the world in terms of anticoagulation care.",
            "This is data taken from reliant and you can see the current standard of antique wagon care in Sweden is the best in the world.",
            "77% TTR in the UK UK is number 4 or #5 in the world with 72% so we were using two countries where the standard of anticoagulation care is very good and Despite that we were able to show.",
            "Genotyped dosing algorithm actually works better in those situations."
        ],
        [
            "And this is some unpublished data between comparing COAG and you packed, and we've what we've done here is looked at the total number of variants.",
            "This includes variants in two C9 as well as variance in vitamin K. Box Art is complex, and you can categorize them as having one variant or greater than one variant.",
            "And what we find is that overall in COAG there were more people with no variance compared to EU packed.",
            "And we had more higher frequency of patients with at least one variant 52% compared to 36%.",
            "So Becausw they had a much higher African population overall number of variants that they were actually identifying, or much less than we were in our population in our study."
        ],
        [
            "The importance of this is perhaps seen in this slide.",
            "Is that what happened with our algorithm?",
            "Was it worked better if you had variance?",
            "So if you didn't have any variance, you wild type for both vehicles.",
            "See one ship to see nine.",
            "The algorithm didn't really make much difference.",
            "You can see there was no difference, only 2% difference between the genotyping control arm OK and P value was nonsignificant.",
            "If you had one variant that led to 7% difference between the genotyping control arm, which is highly significant.",
            "And then if you had two more variants that lead to an 11% decrease in a difference between the genotyped arm and control arm with a highly significant P value.",
            "So it tells you the algorithm was particularly suitable for those who had the variance and was actually working better in those wide variants.",
            "And those are the people who really need the genotype guiding our dosing algorithm.",
            "If you wild type, it doesn't matter what your dosing is, doesn't matter how bad your doctors are.",
            "You probably going to be alright on Warfrin.",
            "In terms of our in our control, but if you do have a variant and that's at least 30% of the population that you don't need this genotype guided algorithm and data from the literature shows at 10% improvement in percent ETR.",
            "And we got 11% leads to 20% improvement in clinical outcomes.",
            "OK, so that's my perspective on, you know, kind of differences that occur between the Warframe you packed study and the COAG study.",
            "And the next aspect for us is to start implementing that in a real world situation as well as undertakers defective."
        ],
        [
            "Yes, the third trial that was published in the Journal of Nuclear Medicine was on the vitamin categories which are used in mainland Europe, Germany, Netherlands, Greece and so on.",
            "And if you look at the literature for asynchronous recruitment, there's certainly data showing the two scenery.",
            "Kosi one are very important and these investigators were able to put into seen on Vico C1 Gina types.",
            "They found there's no difference in three months, but percent ETR was higher.",
            "In genotype time in the first 4 weeks.",
            "But what they had done is that they combined the data from a snow kumral Ann from procurement to give a total of 273 but individual individually the drugs there was only 119 Daisaku Milam and 83 in different Roku Manam.",
            "So assessed individually, the trials were really very underpowered, but putting them together is when they were able to do the statistical analysis.",
            "The question that you have to ask is that these drugs are completely different in terms of the pharmacology.",
            "The half lives how they metabolised was it the right thing to do to combine them together?"
        ],
        [
            "And if you look at the effect of two C9 on the different enantiomers or friend procurement is no common Wolf and you can see that there are marked differences.",
            "So for example, as we said, Eswar friend is a more active enantiomer and two C9 is very important here.",
            "Whereas if you actually look at the Asian Okuma roll, the R 90 miles past more important and two C9 is not so important and you can see that there are three or four and etc are all involved in metabolism of these other anticoagulants.",
            "And maybe more importantly, with regard to warfrin.",
            "And there's also a significant amount of Enpro Kumon, which is excreted unchanged through the kidneys.",
            "So therefore one would have to say that maybe combining the two pharmacologically didn't make sense, and so at the moment the jury is still out as to whether it works for Okumura Nation, Okumura."
        ],
        [
            "So one of the other aspects that we need to contend with in clinical practice in terms of getting things into going to practice, is that there isn't a level playing field.",
            "There is some genetic exceptionalism occurring and release of you know the evidence standards do differ between non genetic and genetic testing and in this particular editorial I gave examples of three different areas and I'm just going to cover drug exposure in terms of genetic except."
        ],
        [
            "Realism, so if you have a drug which is excreted through the kidneys, and if you have a patient with kidney renal impairment, the drug label will tell you to change the dose of that drug based on the kidney impairment.",
            "So here's an example, and there are many different examples like this.",
            "This is a beta lactam, antibiotic aztreonam, and it says that after initial usual dosage, the dosage of aztreonam should be hard in patients with creatinine clearance between 10 to 30.",
            "However, this is all based on PK, PD, modeling OK and PK studies.",
            "It's not based on randomized control trial.",
            "In fact it would be completely impractical to undertake a randomized control trial to implement this into clinical practice.",
            "However, if I have a genetic polymorphism such as 2C9 or two, D6 etc.",
            "Which leads to the same degree of change in drug exposure as renal impairment does.",
            "We are often told that you need a randomized control trial.",
            "We need a prospective study together into clinical practice or change the drug label.",
            "Yet if you have something which is renal failure or renal impairment, you can put down to the label based on PK PD modeling.",
            "So there is a degree of different evidential standards which are required for putting things into clinical practice."
        ],
        [
            "So there may be various reasons for that.",
            "There is unfamiliarity with genetic tests, people also, the physicians maybe have difficulties in interpreting the genetic tests, and also there's a perceived cost of genetic testing.",
            "The cost of genetic.",
            "Obviously the cost of genetic testing is coming down all the time, but I always tell the same to physicians.",
            "You only do test once, once you know your jeans type, you know it.",
            "You don't need to test it again, but if you want to test your renal function, you may have to do 20 times throughout your lifetime.",
            "And there's 20 tests of your renal function are going to cost more than one genetic test.",
            "So so you know, and that is something that needs to be cut across.",
            "And there's sometimes lack of availability of tests, and I've already gone through the port and around time, but there are."
        ],
        [
            "Things coming through in terms of guidelines.",
            "For example, the European Medicines Agency had produced this guidelines, which says that you need to look at pharmacogenetic methodology's in the pharmacokinetic evaluation medicinal products and if you have a particular drug which undergoes clearance, particularly via a specific pathway which is polymorphically expressed, and then you need to undertake dosing evaluation and in the future that those evaluation may be present in new drugs at the beginning in the label so that people dosed differently and in fact.",
            "Examples of this are beginning to appear.",
            "Here's an example."
        ],
        [
            "Drugs in development.",
            "At the moment it's a C met inhibitor.",
            "It's a selective oral, non ATP competitive small molecule inhibitors.",
            "Seemeth which is being used or tested in non small cell lung cancer together in combination with alotta nib and it's metabolised by cytochrome P452C9 and what these investigators did would do actually change.",
            "The dose is based on whether a patient wasn't extensive metabolizer or a poor metabolizer and you can see that in extensive metabolizers they use these kind of doses.",
            "And you can see the kind of at monotherapy and with combination, the kind of air curves that they get.",
            "And in two poor metabolizers they reduced the dose to 120 or 240 milligrams and you can see that the exposure is the same when you reduce the dose in those patients who are extensive metabolizers in poor metabolizers.",
            "And so you're getting exact exposure, same exposure and hopefully you know getting super therapeutic exposure which leads to toxicity.",
            "And clearly these drugs are toxic such as these drugs.",
            "And so if you can limit exposure, you can get same efficacy but reduce toxicity and those kind of things are going to come through.",
            "I think as we move forward in the future."
        ],
        [
            "So I think just to finish off in the last few slides, I think we have to accept that response to drug even is efficacy or toxicity is a complex phenotype very similar to complex diseases?",
            "And really we need to be able to undertake a systems based approaches to be able."
        ],
        [
            "To understand that so if you consider a systems pharmacology approach, you know you will be getting a drug interacting with a particular receptor and you'll be getting the molecular changes which occur as a result of that in terms of the networks which are activated or inhibited at the cellular level and which will lead to tissue level changes in Physiology.",
            "This will then lead to changes in net working within the organ system and Physiology at the level of the organ, which will then eventually lead to the whole body outcome.",
            "In terms of the drug response and we really need to take all that into account in terms of really trying to define how we treat patients on an individualized basis, and in fact."
        ],
        [
            "If we look at Warframe in a way what we have got is a very crude multiscale model.",
            "We have environment where we take these into account.",
            "We have pharmacokinetics which we've taken to these into account pharmacodynamics.",
            "We take this into account, but what we get is about 50 to 60% prediction on the basis that where's the 40%?",
            "And so this is a crude multiscale model and we need to become maybe clever.",
            "And maybe the reason for the differences between the two trials.",
            "Was there were differences in these particular factors which are not being taken into account.",
            "For example, the environmental factors such as alcohol and smoking, or about other P-450 enzymes transcription factors.",
            "What about the metabolism, particularly with respect to pharmacodynamic, determines and is at account for the missing prediction.",
            "So if you take a systems approach, maybe we might get better prediction that may be important for all sorts of all sorts of.",
            "Different phenotypes."
        ],
        [
            "So, just to summarize, I think I'm in time on time.",
            "Yes, that translation to clinical practice is very difficult.",
            "The pathway for translation does Varian, one size does not fit all, just like pharmacogenomics.",
            "One dose does not fatal.",
            "Randomized control trials are certainly not the ultimate answer.",
            "Translating biomarkers into clinical practice, and there is a hierarchy of evidence that people use for for translating things into practice.",
            "I think randomized control trials, as you can see at the top, but we will need to use other kinds of studies, and I think systems based approaches need to be investigated, accompanied by a mechanistic analysis."
        ],
        [
            "If you look into the future, people have suggested that this is suggestion and this might be happening in the UK that in 2019 every child born will have a whole genome sequence done at the time of birth.",
            "We do a pinprick of heel prick anyway at the moment to look for inborn errors of metabolism, but maybe you could actually do whole genome sequences that time.",
            "It may be cheap enough and you have that data within your electronic medical record.",
            "Now, if you have that data within the electronic medical record and you know what the variants are and you have intelligent decision support systems that pops up saying that you're going to go on a 2D6 drug.",
            "Are you going to ignore it or physicians going to ignore it?",
            "So I think the paradigm is changing while we're acquiring randomized control trials at the moment for implementing things into clinical practice as we move forward, I think what will happen is that we will already have that data and then physicians will have to make the choice based on the advice they are given as to whether they change the dose of the drug based on the data that's already available in electronic medical record."
        ],
        [
            "So let me just thank our various people that are involved in some of these studies and and the IUPAC group as well.",
            "Here we are dealers and daily.",
            "Farhad Kamalian, Kalsom, Maitland, and some of the funders that UFB 7 refunding the sort of offering study their Master drug safety Science and Wolfson Foundation funding the other cities.",
            "Thank you very much for your attention.",
            "Thank you for a very clear and comprehensive talk.",
            "Looking at that Warframe trial and was wondering, you see that there's a benefit of the genotyping after 5 to 15 days, would you expect?",
            "Already a benefit was in, for instance, the first 5 days and combined with that you looked at the time any INR in 10 weeks.",
            "Should that not be shorter, so so we chose a long time interval largely to get a better perspective or what the three month over impact was, but the data I showed you was just on TTR where you were showing a different set about 10 days.",
            "But there are differences at the beginning because of the high INR, so the higher now overshoot occurs within the first few days.",
            "So you are seeing the difference.",
            "Early on as well, in some other outcome measures, what everybody does in the literature is just focus on maintenance dose.",
            "But you do need to look at other outcomes such as what the higher INR is at the beginning or the time to reach therapeutic range.",
            "So if you look at the paper in the new gentleman, we've given data on all of those particular outcomes and you do get changes occurring early in other outcomes were not in TTR.",
            "You'd expect the TTR to change later on because of the things that are happening with calculation factors.",
            "Thank you.",
            "No more questions.",
            "Bully.",
            "When you thanks a lot excellent talk, I wonder whether there are any data on.",
            "The role of rare variants in these scenarios.",
            "Do you know of any extrapolations?",
            "I mean, there are data around now.",
            "How many rare variants there are around and what role could they play in this?",
            "And as you know, there are data on rare variants of vitamin K Books ordered this complex with respect to resistance.",
            "There are some rare mutations which lead to patients requiring fifteen 2030 milligrams of warfare in a day, and those were published in nature, and we've identified some other rare variants of between cable service complaints which are unpublished, which showed that you need higher doses.",
            "But there were some patients that that I saw in this trial which which really shot up even though we were using a genotype guided dosing.",
            "Algorithm in them and what we're doing is sequencing the C2C9 at the moment to see whether they had any rare variants within the sub to see nine.",
            "But I think there are probably going to be rare variants in the occasional patients where this algorithm will just not work, and if you look at this of all the dosing algorithms you've done, the correlation you find that at very low doses as well as the very high doses, there's very little correlation.",
            "And so suggesting that there are very many other rare variants that need to be identified, particularly those extreme phenotypes.",
            "No more questions please.",
            "Thank you for a very interesting talk.",
            "Do you think that there is enroll for cytochrome P454F2 that might explain some of the variability that you see?",
            "Not really.",
            "So if you look at we have got data on for F2 and so on.",
            "It only accounts for about 5% of variation.",
            "So even when you do sensitivity analysis of .5% between the two, it really doesn't explain it.",
            "I know that the gift trial which is going on at the moment.",
            "Does incorporate 4F2 but four F2 hasn't really been completely defined and and so you know because there is a huge amount of linkage disequilibrium going on across the 4F cluster with snips in four F-11, which may have an opposite effect for F2.",
            "So I think 4F2 has an effect, but it's very small and the way it may have an effect may also depend on other snips in the 4F cluster which haven't been properly characterized.",
            "Money I have a question.",
            "Honestly saying it's really amazing to see that US trial will not consider all these limitations you mentioned, because in principle ethnicity of frequency distribution of variances is basic form genetics.",
            "Why do you believe that these limitations or CS issues are not considered?",
            "Before before yeah initiation of the US trial.",
            "So obviously I can't answer with the US trial.",
            "Nobody has seen you mentioned.",
            "You should wonderful that in principle there really major limitations in terms of some.",
            "Yeah, I'm issues, so there may be COAG investigators in the audience who may disagree with me and they may have their own interpretation.",
            "This is my interpretation, but my feeling is that what they were trying to do was to reflect the clinical practice in the US.",
            "So in the US they don't use a loading dose algorithm, so they were trying to use what the current standard is.",
            "And obviously part of the population in the areas that we're looking at is much more heterogeneous in the populations that we were looking at, so that you know.",
            "And it was.",
            "You can't really exclude certain populations because ethnicity in taking part in trials so that that led to problems, but I guess they could have thought about changing the algorithm in those individuals and so on.",
            "I guess the issue of why that include two C9 and A1, which seems a bit strange to me because a lot of the work that's been done.",
            "Has been based on maintenance dose in throughout the world and that's what they focused on.",
            "But actually at the beginning you don't need maintenance dose.",
            "You need other parameters how high you are in Argos and so on.",
            "So the algorithm at the beginning is actually different from the algorithm that you get a three months, so you know.",
            "And that was part of the problem as well I think.",
            "So I think focusing too much on maintenance dose leads to problems in terms of what happens at the beginning, which is what the difference was between the two trials between day and 1.",
            "Three.",
            "OK. No more questions.",
            "The only one coming but are currently the current practice in UK.",
            "Do you use for testing buffering algorithm for clinical practice?",
            "So at the moment the standard practices that we give a loading those 10, five, 5 or 1010 five depending which hospital you're in?",
            "If you're elderly, you give 555 for the first days.",
            "There's no genetic testing going on at the moment, but what we're about to start is an implementation study in some real world practices in the Community with general practices whereby they're going to Geno type in a real world setting and then compare that to other studies to see whether it works in real world setting.",
            "Not randomized, just everybody coming to the clinic, and so if we can do that kind of implementation and show it works and do the cost effectiveness around it, then we can actually start putting things into guidelines and so on, OK?",
            "Dope moon yeah thank you so much for your talking to this introduction pharmacogenomics today, so and now.",
            "It's time for coffee."
        ]
    ],
    "summarization": {
        "clip_0": {
            "is_summarization_sample": false,
            "summarization_data": [
                {
                    "sent": "It's great to be here and thank you for the invitation to come to the MDO.",
                    "label": 0
                },
                {
                    "sent": "So I'm a clinician and I am going to give you a very translational talk.",
                    "label": 0
                },
                {
                    "sent": "I will try to disperse that with some mechanisms.",
                    "label": 0
                },
                {
                    "sent": "So.",
                    "label": 0
                },
                {
                    "sent": "I was given this particular title, so in order to fulfill this particular title, I really need to take you through what happens in clinical practice and then tell you about the difficulties of implementing biomarkers into clinical practice.",
                    "label": 0
                },
                {
                    "sent": "Oops, not working.",
                    "label": 0
                },
                {
                    "sent": "So.",
                    "label": 0
                }
            ]
        },
        "clip_1": {
            "is_summarization_sample": true,
            "summarization_data": [
                {
                    "sent": "2.",
                    "label": 0
                },
                {
                    "sent": "If you talk to physicians, they will tell you that they've been personalizing treatments for centuries, and in a way, when I see a patient, I use the best evidence that's available to me, usually from randomized control trials.",
                    "label": 0
                },
                {
                    "sent": "Which are population based studies really to treat the patient was in front of me in the surgery.",
                    "label": 1
                },
                {
                    "sent": "So I'm going from population level evidence to try to extrapolate that to the individual, and that's always difficult.",
                    "label": 0
                },
                {
                    "sent": "This has proven benefits from a population perspective, but it's less difficult.",
                    "label": 1
                },
                {
                    "sent": "It's more difficult to predict at an individual level.",
                    "label": 0
                },
                {
                    "sent": "We can't predict whether an individual get side effect and how severe the side effect will be, and we can't predict whether the patient will improve in response to the drug that I give to them.",
                    "label": 1
                },
                {
                    "sent": "And that creates problems and we've known.",
                    "label": 0
                }
            ]
        },
        "clip_2": {
            "is_summarization_sample": true,
            "summarization_data": [
                {
                    "sent": "About the fact that there is variability in responses to drugs and this is taken from the Physicians desk reference and it basically shows you what their efficacy rate is and this is a slide that almost everybody uses in this area and talking about pharmacogenetics and so on.",
                    "label": 0
                },
                {
                    "sent": "And Alan Roses who was previous GSK vice president, was very honest when he gave a talk in London at the DIA Conference.",
                    "label": 0
                },
                {
                    "sent": "Instead, the vast majority of drugs more than 90%.",
                    "label": 1
                },
                {
                    "sent": "Only working 30 to 50% of people and a journalist was in the audience and you can see ended up on the front page of a newspaper in the UK the next day.",
                    "label": 0
                },
                {
                    "sent": "He had to go in front of the chief executive at GSK to tell them why the share price has gone down.",
                    "label": 0
                },
                {
                    "sent": "So you have to be careful what you say, so I hope they know journalists.",
                    "label": 0
                }
            ]
        },
        "clip_3": {
            "is_summarization_sample": true,
            "summarization_data": [
                {
                    "sent": "The other problem is that you do get adverse drug reactions, and we've done some of the biggest studies in the world, and there are other studies in the United States as well, and at the moment in the United Kingdom, if you will look at the whole bed base in the whole healthcare system, 8000 beds are occupied for patients with adverse drug reactions, not all of them are related to genetics.",
                    "label": 0
                },
                {
                    "sent": "Some of them are related to poor prescribing and so on.",
                    "label": 0
                },
                {
                    "sent": "But nevertheless there are severe reactions such as this toxic epidermal necrolysis.",
                    "label": 1
                },
                {
                    "sent": "Which are related to genetics an if we had some genetic input into the way we look after patients, we could reduce some of them and it's been estimated that we could probably reduce about 30% of adverse drug reactions considering the costs.",
                    "label": 0
                },
                {
                    "sent": "the UK healthcare system by 1 billion pounds a year, then that's still a big saving by incorporating genetics.",
                    "label": 0
                }
            ]
        },
        "clip_4": {
            "is_summarization_sample": true,
            "summarization_data": [
                {
                    "sent": "So this is my concept of where pharmacogenetics fits in into the whole structure of personalized medicine.",
                    "label": 1
                },
                {
                    "sent": "You know that people talk about personalized medicine, to talk about precision medicine.",
                    "label": 0
                },
                {
                    "sent": "They talk about stratified medicine, and at the moment what we do when we treat patients is really based on definitions of disease which span back to the 19th and 20th century where we take a disease is a phenotypic definition.",
                    "label": 0
                },
                {
                    "sent": "What symptoms the patient has was science.",
                    "label": 0
                },
                {
                    "sent": "The patient has what the histologies of their disease and and that's the current standard.",
                    "label": 1
                },
                {
                    "sent": "But as we learn more about disease.",
                    "label": 0
                }
            ]
        },
        "clip_5": {
            "is_summarization_sample": false,
            "summarization_data": [
                {
                    "sent": "And we learn about the molecular subtypes of disease.",
                    "label": 0
                },
                {
                    "sent": "We're going to be able to stratify disease into different strata, so inflammatory bowel disease won't be one disease.",
                    "label": 0
                },
                {
                    "sent": "It will be many different strata of disease, and that disease stratification is going to be very important in terms of determining which treatment a patient needs.",
                    "label": 0
                },
                {
                    "sent": "But even when you look at different disease strata.",
                    "label": 0
                },
                {
                    "sent": "And you start to give therapies within those different disease strata then.",
                    "label": 0
                }
            ]
        },
        "clip_6": {
            "is_summarization_sample": false,
            "summarization_data": [
                {
                    "sent": "You will still going to have variability in the way our drugs work in that disease, and this is where pharmacogenomics comes in to be able to define how the drug is handled in their individual in that disease stratum, as well as how it's it causes adverse effects but.",
                    "label": 0
                }
            ]
        },
        "clip_7": {
            "is_summarization_sample": true,
            "summarization_data": [
                {
                    "sent": "Mostly patients are all different.",
                    "label": 0
                },
                {
                    "sent": "They drink, they smoke, they eat differently.",
                    "label": 0
                },
                {
                    "sent": "They have different weights, etc.",
                    "label": 0
                },
                {
                    "sent": "And we need to take that into account when we treat patients as well, and only when you can take all these factors into account.",
                    "label": 0
                },
                {
                    "sent": "Environmental drug variability, molecular definition, etc.",
                    "label": 1
                },
                {
                    "sent": "That you can really practice personalized medicine, so it's a tough ask to be able to take all these into account and in a way for those systems biologists here, you've got a multi scale model.",
                    "label": 0
                },
                {
                    "sent": "Yeah, and you'll be able to need to fulfill a multiscale model to be able to really come out with the key decisions as to which drug is best in which patient.",
                    "label": 0
                }
            ]
        },
        "clip_8": {
            "is_summarization_sample": true,
            "summarization_data": [
                {
                    "sent": "So when people look at pharmacogenomic variation in drug response, I don't need to obviously label this point with this audience.",
                    "label": 1
                },
                {
                    "sent": "You can generally divide it into pharmacokinetics, adme or pharmacodynamics and so on, and the different drug targets on the slide.",
                    "label": 0
                },
                {
                    "sent": "But what you do have in many cases is that you have both pharmacokinetic determines and pharmacodynamic risk determinants.",
                    "label": 0
                },
                {
                    "sent": "And I'll come back to that later on.",
                    "label": 0
                },
                {
                    "sent": "But if you look at the literature we've mostly concentrated on pharmacokinetics in terms of pharmacogenomics, but maybe pharmacodynamic targets are much more important in terms of determining response, but we need to be able to look at that together.",
                    "label": 0
                }
            ]
        },
        "clip_9": {
            "is_summarization_sample": true,
            "summarization_data": [
                {
                    "sent": "So.",
                    "label": 0
                },
                {
                    "sent": "When you look at human genomic variation individualization drug treatment, there are examples when it works beautifully and I'm going to go through that.",
                    "label": 1
                },
                {
                    "sent": "One example of that in an area that we work in, which is HLA.",
                    "label": 0
                }
            ]
        },
        "clip_10": {
            "is_summarization_sample": true,
            "summarization_data": [
                {
                    "sent": "An HLA is the perhaps most polymorphic region, or the MHC is the most polymorphic region of the human genome is on the short arm of chromosome 6, and there are three different regions of chromosomes HLA that is class one ABC Class 2 DRD CDP and in between class One and Class 2 is the Class 3 region where you have heat shock protein, tumor necrosis factor Alpha, and Micah.",
                    "label": 0
                },
                {
                    "sent": "And and these this particular region is in important in protecting people from infectious diseases.",
                    "label": 0
                },
                {
                    "sent": "That's how we Mount an immune response to the virus is that we get orders of bacteria that were infected with also important in autoimmune diseases.",
                    "label": 0
                },
                {
                    "sent": "But it's also important in immune mediated adverse drug reactions such as the picture I showed you before of toxic, epidermal necrolysis and if you look at the literature since 2001 since the beginning of this century, they've been 23.",
                    "label": 0
                },
                {
                    "sent": "Different HLA associations which have been associated with the HLA genes and some most of them are at a genomewide significant level, so that's an enormous amount of work that's been done in this area and very very important findings for 23 different associations with different drugs with adverse drug reactions affecting not only the skin but also liver.",
                    "label": 1
                },
                {
                    "sent": "And you'll hear about liver injury later on today.",
                    "label": 0
                }
            ]
        },
        "clip_11": {
            "is_summarization_sample": false,
            "summarization_data": [
                {
                    "sent": "And perhaps the best example of that is with the drug abacavir, which everybody knows about, but it's important to go through how well it went into the literature, but also some other benefits it has so back of ear causes this hypersensitivity reaction.",
                    "label": 0
                },
                {
                    "sent": "Which is a skin rash, generalized, systemic manifestations, etc and work undertaken in Australia and then in North America and then also by our so.",
                    "label": 0
                }
            ]
        },
        "clip_12": {
            "is_summarization_sample": false,
            "summarization_data": [
                {
                    "sent": "Else was able to show very strong Association with HLA B Star 5701.",
                    "label": 0
                },
                {
                    "sent": "Now to get it into clinical practice you need to undergo various different steps and one of those is to show that it is cost effective.",
                    "label": 0
                }
            ]
        },
        "clip_13": {
            "is_summarization_sample": true,
            "summarization_data": [
                {
                    "sent": "To be able to incorporate that into clinical system.",
                    "label": 0
                },
                {
                    "sent": "So we ask the simple question, would it be cost effective to introduce H 57 one typing into the UK National Health Service and would that save money for the UK National Health Service?",
                    "label": 0
                },
                {
                    "sent": "And we understood we constructed various models, economic models and so on.",
                    "label": 0
                },
                {
                    "sent": "And we came out with a conclusion there.",
                    "label": 0
                },
                {
                    "sent": "Yes, it would be cost effective and this paper was published in Pharmaco Genetics in 2004 and by 2006 every patient in the UK was getting 57.",
                    "label": 1
                },
                {
                    "sent": "One test to prevent abacavir hypersensitivity.",
                    "label": 1
                },
                {
                    "sent": "So two years in translation, which is a fantastic outcome and tells you that when it does work.",
                    "label": 0
                },
                {
                    "sent": "It can work very well and really does make a difference.",
                    "label": 0
                },
                {
                    "sent": "Ah.",
                    "label": 0
                }
            ]
        },
        "clip_14": {
            "is_summarization_sample": false,
            "summarization_data": [
                {
                    "sent": "In fact, the net effect of there has been dramatic.",
                    "label": 0
                },
                {
                    "sent": "So if you look at the frequency before testing, pre testing was 7% in Australia less than 1% in France went from 12% to 0% in the UK clinic in London went from 8% to 2% and the 2% was higher than it should have been because one patient was given the drug before they had the test result and that tells you the problem of the you need the test result quickly if you're going to prescribe a drug based on the test.",
                    "label": 0
                },
                {
                    "sent": "You can't wait for two weeks to get a test result, so turn around time because important as part of the translation pathway.",
                    "label": 0
                }
            ]
        },
        "clip_15": {
            "is_summarization_sample": false,
            "summarization_data": [
                {
                    "sent": "And this is what it's done in terms of usage of the drug.",
                    "label": 0
                },
                {
                    "sent": "And this is only data till 2009.",
                    "label": 0
                },
                {
                    "sent": "But this is what happened when we started introducing it in the UK and these are some of the red is the number of HLA tests which occurred in the UK.",
                    "label": 0
                },
                {
                    "sent": "And if you look at Kivexa, which is abacavir before the test was introduced, the usage was very low.",
                    "label": 0
                },
                {
                    "sent": "But you can see in parallel the Kivexa usage went up, while the usage of other drugs so just come over, and so on went down.",
                    "label": 0
                },
                {
                    "sent": "So while people worry about the fact that if you're going to introduce testing, it's going to reduce the use of your drug, because people won't be bothered testing or will be too expensive.",
                    "label": 0
                },
                {
                    "sent": "What you can actually showing here is that introducing a genetic test actually increased the use of the drug.",
                    "label": 0
                },
                {
                    "sent": "Because the physicians became more confident using it and patients became more confident in taking the drug.",
                    "label": 0
                },
                {
                    "sent": "So genetics was working for actually using the drug in clinical practice.",
                    "label": 0
                },
                {
                    "sent": "Importantly, this particular genetic finding has also led to important mechanistic findings, and that's where something that we always always try to tend to ignore is that pharmacogenetic associations, even you can't put them into clinical practice, actually can give you a lot of information about mechanisms.",
                    "label": 0
                }
            ]
        },
        "clip_16": {
            "is_summarization_sample": false,
            "summarization_data": [
                {
                    "sent": "And and a year or two ago, three papers came out almost simultaneously, one in nature, one in PNS and one in AIDS, which showed that the mechanism are potential mechanism.",
                    "label": 0
                },
                {
                    "sent": "There are other mechanisms as well about how abacavir maybe binding to the 57 one and therefore inducing an immune reaction.",
                    "label": 0
                },
                {
                    "sent": "And this is shown here.",
                    "label": 0
                }
            ]
        },
        "clip_17": {
            "is_summarization_sample": true,
            "summarization_data": [
                {
                    "sent": "And this is the cleft MHC cleft for 57.",
                    "label": 0
                },
                {
                    "sent": "One with the F Pocket we're back of his tour to bind.",
                    "label": 0
                },
                {
                    "sent": "And normally when they serve in its resting state, there are peptides within the MHC cleft.",
                    "label": 0
                },
                {
                    "sent": "But when patients with 57 one are exposed to abacavir, the abacavir goes and binds to this MHC cleft and displaces some of these peptides.",
                    "label": 0
                },
                {
                    "sent": "And if you look at the peptides pet do peptide elution from this and look at some of the peptides, you start showing novel self peptides when the back of his present within the cleft.",
                    "label": 0
                },
                {
                    "sent": "And these novel self peptides have isoleucine, leucine, occupying C terminal anchor proteins rather than the conventional peptides which are present.",
                    "label": 0
                },
                {
                    "sent": "So water back of is doing is displacing the normal peptide compliment and a different peptide compliment is coming through.",
                    "label": 0
                },
                {
                    "sent": "And then I'll turn it.",
                    "label": 0
                },
                {
                    "sent": "Peptide complement is recognized as being foreign, and that induces an immune reaction and it's very neat hypothesis.",
                    "label": 0
                },
                {
                    "sent": "It's only been proven in vitro, but nevertheless now it needs to be some further work needs to be done to be able to prove that.",
                    "label": 0
                },
                {
                    "sent": "In vivo and if you look at closely related other types such as 5703, there's no change in peptide profile, so it's very very specific for 5701 and tells you about the specificity and define some ways of how drugs can interact with very specific, I mean acid molecules within very specific binding pockets within the MHC.",
                    "label": 1
                }
            ]
        },
        "clip_18": {
            "is_summarization_sample": false,
            "summarization_data": [
                {
                    "sent": "Another example, how where it actually makes sense that genomic variation is important, and this is an example which is from.",
                    "label": 0
                }
            ]
        },
        "clip_19": {
            "is_summarization_sample": true,
            "summarization_data": [
                {
                    "sent": "That's not our example.",
                    "label": 0
                },
                {
                    "sent": "It's from the new Jenna Mattson published early this year and this is in a condition rare condition called peroxisomal nocturnal hemoglobin area in a normal red blood cell.",
                    "label": 0
                },
                {
                    "sent": "What you have so you have G protein anchored proteins and these were such a CD55 CD.",
                    "label": 0
                },
                {
                    "sent": "59 and when you have compliments such as C5 it binds to this proteins and you can prevent hemolysis.",
                    "label": 0
                },
                {
                    "sent": "But if you haven't.",
                    "label": 0
                },
                {
                    "sent": "Absence of this and this is somatic mutation is not.",
                    "label": 0
                },
                {
                    "sent": "An acquired mutation is somatic mutation.",
                    "label": 0
                },
                {
                    "sent": "You lose the ability to be able to bind these, purchase the surface compliment goes in and causes hemolysis.",
                    "label": 0
                },
                {
                    "sent": "Not only do get hemolysis of red blood cells, but you get thrombosis and Sciences very severe disease process with nocturnal hemoglobin, nuria and these GPI anchored protein CD fifty five 7059 are absent because this somatic mutation.",
                    "label": 0
                },
                {
                    "sent": "So there is a monoclonal antibody humanized monoclonal antibody called.",
                    "label": 0
                },
                {
                    "sent": "Eckel is a map which binds to C5, inhibits an activation, but 3% of patients have a poor response.",
                    "label": 1
                },
                {
                    "sent": "They don't respond to Equalism app.",
                    "label": 0
                }
            ]
        },
        "clip_20": {
            "is_summarization_sample": true,
            "summarization_data": [
                {
                    "sent": "And so these investigators in Japan started looking at those 3% of patients and found that there is a missense mutation identified the C5 complement gene.",
                    "label": 1
                },
                {
                    "sent": "And when they did some in vitro studies, they were able to show that while Equalism is able to block C5 media team olisis in non mutant red blood cells, it can't do that in the those carrying the variant.",
                    "label": 0
                },
                {
                    "sent": "And you can see those patients with a Japanese patient with poor response had this Miss sense here and the Argentinian patient had poor response.",
                    "label": 0
                },
                {
                    "sent": "As well, so this is something that actually makes sense because you know, it's a drug target and you can actually show where there's difference.",
                    "label": 0
                },
                {
                    "sent": "You may get differences in binding to something which is very specific, such as Eckel is a map.",
                    "label": 0
                }
            ]
        },
        "clip_21": {
            "is_summarization_sample": false,
            "summarization_data": [
                {
                    "sent": "But so those are the kind of gold standards.",
                    "label": 0
                },
                {
                    "sent": "If you like.",
                    "label": 0
                },
                {
                    "sent": "Usually it's much more difficult, and I'm going to take you through some of the difficulties.",
                    "label": 0
                },
                {
                    "sent": "And it's been an given, the audience, and so on.",
                    "label": 0
                },
                {
                    "sent": "I'm going to concentrate particularly hopeful.",
                    "label": 0
                }
            ]
        },
        "clip_22": {
            "is_summarization_sample": true,
            "summarization_data": [
                {
                    "sent": "On more on pharmacokinetics and if you look at the sources of variation and there are an increasing number of examples of pharmacodynamic genetic variations which are being used in clinical practice, such as the B RAF mutation, which is now found in malignant Melanoma in thyroid cancer as well as in hairy cell leukemia, and you have drugs such as very rough and which can interact with that be reputation and cause regression of that cancer, at least for a short time.",
                    "label": 1
                },
                {
                    "sent": "But pharmacokinetic variation has been much more difficult to implement to clinical practice.",
                    "label": 1
                },
                {
                    "sent": "Perhaps the most successful has been therapure in methyltransferase, which deficiency causes bone marrow suppression.",
                    "label": 0
                },
                {
                    "sent": "With six mercaptopurine azathioprine, that's probably the most successful farm kinetic variation implementing clinical practice.",
                    "label": 0
                },
                {
                    "sent": "But I think it is important to note that PK and PD factors work together, and I think taking account about those can improve prediction and warfrin is a specific example where we worked on and they've been two trials published recently with which created a lot of confusion.",
                    "label": 0
                },
                {
                    "sent": "So I'm going to take you through the Warframe story and tell you about possible potential reasons why there's been differences between two different trials recently.",
                    "label": 0
                },
                {
                    "sent": "Trying to relate it to pharmacology and P-450 particularly C9.",
                    "label": 0
                },
                {
                    "sent": "So what?",
                    "label": 0
                }
            ]
        },
        "clip_23": {
            "is_summarization_sample": false,
            "summarization_data": [
                {
                    "sent": "Is a very widely used vitamin K antagonist at 1% of the UK population.",
                    "label": 0
                },
                {
                    "sent": "Use it.",
                    "label": 0
                },
                {
                    "sent": "The problem with warfrin as you know is that you can't predict the doses of 44 variability in dosage.",
                    "label": 0
                },
                {
                    "sent": "And if you look at any epidemiological studies, you find that Warren is in the top three of drugs which cause hospital admission because of bleeding, such as in this patient, and so on.",
                    "label": 0
                },
                {
                    "sent": "So despite the fact that warframe's been around for 60 years and we are still having difficulty in using it and it still causes a lot of problems.",
                    "label": 0
                },
                {
                    "sent": "So the question that everybody's been looking at is can you predict dose with Warframe?",
                    "label": 0
                }
            ]
        },
        "clip_24": {
            "is_summarization_sample": false,
            "summarization_data": [
                {
                    "sent": "And you really need to go to the metabolism of offering and the way Warren acts to be able to try to define what may be important so often is administered as at arness, warfare enantiomers and the S enantiomer is the more active enantiomer, and cytochrome P452C9 is responsible for the metabolism of S warfrin.",
                    "label": 0
                },
                {
                    "sent": "WARFRIN binds to vitamin K booksellers complex, inhibiting it and therefore preventing the formation of activated clotting factors 279 and 10.",
                    "label": 0
                },
                {
                    "sent": "And So what we have is a combination of pharmacokinetic factors as well as pharmacodynamic factors which actually then lead to the overall effect of Warframe which is anticoagulation.",
                    "label": 0
                },
                {
                    "sent": "And we measure that using the international normalized ratio and try to keep it between two and three in most indications so work has been going on.",
                    "label": 0
                }
            ]
        },
        "clip_25": {
            "is_summarization_sample": true,
            "summarization_data": [
                {
                    "sent": "To identify genetic factors in this and this by many different groups all over the world, including ourselves.",
                    "label": 0
                },
                {
                    "sent": "And I'll come back to that in a minute.",
                    "label": 0
                },
                {
                    "sent": "So one of the problems is how much of this of problems that you get with warfrin is related to an ion are which is a biomarker that we use now.",
                    "label": 0
                },
                {
                    "sent": "You can see that the response is quite different in different individuals in terms of dose variation, and if you get a high INR your rate of bleeding goes up.",
                    "label": 0
                },
                {
                    "sent": "So if you're above 4.1 rate of bleeding is 99.26 compared to somebody who's got a much lower INR.",
                    "label": 0
                },
                {
                    "sent": "But if you actually look at the literature.",
                    "label": 0
                },
                {
                    "sent": "Only 50% of bleeds that occur with warfrin, which is what we're trying to prevent, occur with an INR greater than two point 550% occur at levels below this.",
                    "label": 1
                },
                {
                    "sent": "So if you're going to try to implement.",
                    "label": 0
                },
                {
                    "sent": "War friend dose prediction and base it on Ion.",
                    "label": 0
                },
                {
                    "sent": "Are you only going to succeed 50% of the time with 50% of the time you're not going to succeed anyway, so your success rate is already being cut down by 50%.",
                    "label": 0
                },
                {
                    "sent": "And that makes it difficult to then implement that into clinical practice.",
                    "label": 0
                },
                {
                    "sent": "So.",
                    "label": 0
                }
            ]
        },
        "clip_26": {
            "is_summarization_sample": true,
            "summarization_data": [
                {
                    "sent": "Work which is undertaken in many different areas of the world, including by ourselves, has shown that there are environmental factors, clinical factors as well as genetic factors important in determining what the dose of warfarin is that you require every day.",
                    "label": 0
                },
                {
                    "sent": "So there are the clinical factors such as age, height and weight.",
                    "label": 0
                },
                {
                    "sent": "10 to 20% is what they account for in terms of dose variation, and that's been known since the 1970s and 1980s.",
                    "label": 0
                },
                {
                    "sent": "Then there are drug interactions and I'm your drone.",
                    "label": 0
                },
                {
                    "sent": "Particularly important here, about 5 to 10% in terms of accounting for dose variation.",
                    "label": 0
                },
                {
                    "sent": "Then there are genetic factors and genetic factors.",
                    "label": 0
                },
                {
                    "sent": "Overall account for greater part of what determines their or anticoagulation control.",
                    "label": 1
                },
                {
                    "sent": "So cytochrome P452C9, particularly the start and start three alleles account for 15% of those variation and vitamin K project complex accounts for about 25% of the dose variation.",
                    "label": 0
                },
                {
                    "sent": "And so if you look at the literature.",
                    "label": 0
                }
            ]
        },
        "clip_27": {
            "is_summarization_sample": true,
            "summarization_data": [
                {
                    "sent": "And look at all the data on Warfrin Warfrin and the two C9 V Coc.",
                    "label": 0
                },
                {
                    "sent": "One genetics has been replicated almost everywhere in every population, and so this is one of the most highly replicated genotype phenotype associations in the world.",
                    "label": 1
                },
                {
                    "sent": "And so you know which which is important, because as you know, with many different genetic associations we have difficulties in replicating.",
                    "label": 0
                }
            ]
        },
        "clip_28": {
            "is_summarization_sample": true,
            "summarization_data": [
                {
                    "sent": "And so are there any other genetic factors?",
                    "label": 0
                },
                {
                    "sent": "This is data from our unpublished G was that we had taken in 714 patients and what we're looking at is war for the mean weekly dose.",
                    "label": 1
                },
                {
                    "sent": "For those of you who do not know exactly what all this stands for, then on this you have each of the individual chromosomes up to chromosome 22 and then on the Y axis is a minus log 10 P value and this is called a Manhattan plot.",
                    "label": 0
                },
                {
                    "sent": "But what you find is that there are only two peaks coming up here.",
                    "label": 0
                },
                {
                    "sent": "You know one for cytochrome P42C9 in Crimson 10, another one for vitamin K Pixel is complex and chromosome 16.",
                    "label": 0
                },
                {
                    "sent": "So despite the fact that you know we looked at so many different million snips across this, we couldn't find anything in literature.",
                    "label": 0
                },
                {
                    "sent": "People have been able to find anything there is cytochrome P-450 or 4F2.",
                    "label": 0
                },
                {
                    "sent": "We only accounts .5 to 1% of the dose variation.",
                    "label": 0
                },
                {
                    "sent": "And that certainly didn't show up in our particular study.",
                    "label": 0
                },
                {
                    "sent": "So based on that.",
                    "label": 0
                },
                {
                    "sent": "Then one could say that we will need to develop algorithms and so on, and people have.",
                    "label": 0
                }
            ]
        },
        "clip_29": {
            "is_summarization_sample": false,
            "summarization_data": [
                {
                    "sent": "Come together all around the world an and in the area of genetic Association studies and so on.",
                    "label": 0
                },
                {
                    "sent": "It is important to have consortia working together and pulling data so that you can get better power in terms of what you do.",
                    "label": 0
                },
                {
                    "sent": "So we published this as part of the International War Frank Genetic Consortium.",
                    "label": 0
                },
                {
                    "sent": "In the new General medicine and developed dosing algorithms dosing algorithms which contain the genetic data as well as dosing algorithms which contain clinical data and this has been the basis of what the trials.",
                    "label": 0
                },
                {
                    "sent": "That will be undertaken.",
                    "label": 0
                },
                {
                    "sent": "Have utilized these kind of algorithms.",
                    "label": 0
                }
            ]
        },
        "clip_30": {
            "is_summarization_sample": true,
            "summarization_data": [
                {
                    "sent": "So there have been several trials going on around the world and and the the trial in the EU, which I was involved in, was been sponsored by the European Commission and the trial was being undertaken in the United Kingdom and in Sweden because these two countries use Warframe, but there were two other trials.",
                    "label": 0
                },
                {
                    "sent": "One was unfair pro Kumon and the other one was an Acer camera which were being undertaken.",
                    "label": 0
                },
                {
                    "sent": "Other parts of Europe where those particular vitamin can techniques are being used.",
                    "label": 0
                },
                {
                    "sent": "And and the design was quite simple, while relatively simple in that you patient was recruited to the study.",
                    "label": 0
                },
                {
                    "sent": "They were randomized to receive either genotype guided care or standard care, and So what happens in the patient is randomized to genotype guided care is that we take a small amount of blood about one mil.",
                    "label": 0
                },
                {
                    "sent": "We put this into the point of care test.",
                    "label": 1
                },
                {
                    "sent": "Here we are working with a company called LG See in London who are a partner in this U grant.",
                    "label": 0
                },
                {
                    "sent": "And this particular point of care platform gives you results on three alleles.",
                    "label": 0
                },
                {
                    "sent": "That is start to start Re and Vico C1 in 2 hours and you put the results of the Geno types into computer dosing algorithm, which then tells you what the dose should be for the first three days for the genotype guided arm and what we then did was to compare it to standard care standard care at the moment in the UK and Sweden is that you give a loading dose at the beginning.",
                    "label": 0
                },
                {
                    "sent": "A standard dose 10 five 5 is what we used and then we compare the 10 five 5 milligrams versus the individualized dose and the important thing was at the same time we could actually test the utility of a point of care test.",
                    "label": 0
                }
            ]
        },
        "clip_31": {
            "is_summarization_sample": true,
            "summarization_data": [
                {
                    "sent": "And so we published this in the New England Journal of Medicine just before Christmas, about December last year.",
                    "label": 0
                },
                {
                    "sent": "And what we found is shown on this particular slide with two different kinds of analysis, something called an intention to treat analysis in the per protocol analysis.",
                    "label": 0
                },
                {
                    "sent": "And basically if you look at the control arm, first of all, what we got was the time in therapeutic range.",
                    "label": 0
                },
                {
                    "sent": "And this was the primary outcome measure.",
                    "label": 1
                },
                {
                    "sent": "This is a percentage of time in therapeutic range.",
                    "label": 0
                },
                {
                    "sent": "During 12 weeks.",
                    "label": 0
                },
                {
                    "sent": "Follow up after starting Warfar in therapy and 63% percent ETR is very good for three months.",
                    "label": 0
                },
                {
                    "sent": "It's kind of gold standard.",
                    "label": 1
                },
                {
                    "sent": "You rarely get above that with normal Warframe care, but despite the fact that we were had a very good TTR in the control arm, we actually managed to get better one in the Geno, type them and there's 7% difference between genotype and standard dosing with the P value, which is highly significant.",
                    "label": 0
                }
            ]
        },
        "clip_32": {
            "is_summarization_sample": true,
            "summarization_data": [
                {
                    "sent": "And let me just show you in more detail what happened between the different groups and the genotype guided group.",
                    "label": 0
                },
                {
                    "sent": "Here is in blue and the control group is in red and if you look at the international normalized ratio and we try to aim between 2:00 and 3:00 and you can see in the control group you were getting higher values, you were getting overshoot above 3 at the beginning based on the initiation that we did and then in the genotype guided group it was actually better you weren't getting the overshoot and it was much better control.",
                    "label": 0
                },
                {
                    "sent": "Overall remaining about 2.5 throughout, while the control group overshot and then with monitoring, eventually came down to the kind of 2.5 min level.",
                    "label": 0
                },
                {
                    "sent": "And if you look at time in therapeutic range, the control group had worst time in therapeutic range throughout three months.",
                    "label": 0
                },
                {
                    "sent": "But separation between the genotype guided group and Control Group was occurring about 10 to 15 days.",
                    "label": 1
                },
                {
                    "sent": "So within 10 to 15 days you can show a difference with this dosing regiment.",
                    "label": 0
                },
                {
                    "sent": "That genotype dosing regimen was working better in terms of getting patients into the correct range.",
                    "label": 0
                }
            ]
        },
        "clip_33": {
            "is_summarization_sample": true,
            "summarization_data": [
                {
                    "sent": "Now at the same time, in the same issue there was American trials published as well and that's called COAG and that showed no difference between genotyped and control arms.",
                    "label": 1
                },
                {
                    "sent": "Now people say we need control trial randomized control trials to show how we can get biomarkers into clinical practice.",
                    "label": 0
                },
                {
                    "sent": "But there were two controlled trials carried out with different designs were showing completely different results and clearly that is that has created a problem.",
                    "label": 0
                },
                {
                    "sent": "It's created a lot of controversy.",
                    "label": 0
                },
                {
                    "sent": "A lot of debate.",
                    "label": 0
                },
                {
                    "sent": "Anne for example.",
                    "label": 0
                }
            ]
        },
        "clip_34": {
            "is_summarization_sample": true,
            "summarization_data": [
                {
                    "sent": "Genome Web said two conflicting perspective randomized control trials.",
                    "label": 0
                },
                {
                    "sent": "No different guidance to clinicians.",
                    "label": 0
                },
                {
                    "sent": "There was a.",
                    "label": 0
                },
                {
                    "sent": "There was an editorial associated with the two studies, or there were three studies published.",
                    "label": 0
                },
                {
                    "sent": "I'll come back to the third one.",
                    "label": 0
                },
                {
                    "sent": "There was a.",
                    "label": 0
                },
                {
                    "sent": "The tutorial from Bruce Fury.",
                    "label": 0
                },
                {
                    "sent": "And he said the conclusions of the three studies are similar.",
                    "label": 1
                },
                {
                    "sent": "Now maybe he was reading a different trial than I was, but the trial that we had in EU pact versus the COAG had different results.",
                    "label": 0
                },
                {
                    "sent": "One showed it worked once, showed it didn't work, and he said it was similar.",
                    "label": 0
                },
                {
                    "sent": "So I don't think he could explain the reason, so he just decided to take the easy option.",
                    "label": 0
                }
            ]
        },
        "clip_35": {
            "is_summarization_sample": false,
            "summarization_data": [
                {
                    "sent": "So let me show you why I think that there were different and this is my interpretation.",
                    "label": 0
                },
                {
                    "sent": "Obviously people from COAG may have a different operation, so you can either be in a pessimist and you can say that your glass is half empty, or you can be optimised like I am says half full and you can really learn things from trials and you can actually learn about the pharmacology and how you put pharmacology into practice and how you integrate that with in genetics to see how you can actually make things work.",
                    "label": 0
                },
                {
                    "sent": "And I'm going to I'm going to take you through.",
                    "label": 0
                }
            ]
        },
        "clip_36": {
            "is_summarization_sample": false,
            "summarization_data": [
                {
                    "sent": "Pharmacological explanation of why there were differences.",
                    "label": 0
                },
                {
                    "sent": "How can we explain the differences?",
                    "label": 0
                }
            ]
        },
        "clip_37": {
            "is_summarization_sample": true,
            "summarization_data": [
                {
                    "sent": "Well, the most important thing if you're going to do a trial which is complex, is that you've got to get the algorithms right.",
                    "label": 0
                },
                {
                    "sent": "And algorithmics strategy between the two different studies was completely different.",
                    "label": 0
                },
                {
                    "sent": "So if you look at you packed what we did was we used a loading dose algorithm.",
                    "label": 1
                },
                {
                    "sent": "That is, we loaded at the beginning for the first 3 days and then we went on to kind of maintenance dose.",
                    "label": 0
                },
                {
                    "sent": "Whereas in COAG there wasn't a loading dose, it was more maintenance dose.",
                    "label": 1
                },
                {
                    "sent": "There was some increase dose on first date but it's based on the maintenance dose.",
                    "label": 0
                },
                {
                    "sent": "They formed a five.",
                    "label": 0
                },
                {
                    "sent": "We use a different algorithm which is decision algorithm But so did COAG.",
                    "label": 0
                },
                {
                    "sent": "And then after from day six, up to three months, we used normal anticoagulant clinics in the UK and Sweden where they use computerized dosing software to be able to dose individual patients in COAG, only followed patients for one month, and it was a protocol driven but really the biggest difference was in day one to three, which in loading this algorithm versus the maintenance dose algorithm.",
                    "label": 0
                },
                {
                    "sent": "Now how can you explain that pharmacologically?",
                    "label": 0
                },
                {
                    "sent": "Why is that important?",
                    "label": 0
                }
            ]
        },
        "clip_38": {
            "is_summarization_sample": true,
            "summarization_data": [
                {
                    "sent": "Well, if you look at S warfrin elimination, half life events warrant is 18 to 35 hours.",
                    "label": 0
                },
                {
                    "sent": "So there is some variation.",
                    "label": 0
                },
                {
                    "sent": "So the time to steady state if you starting a new patient removed from these were all new starters and warfrin will be 92175 hours.",
                    "label": 0
                },
                {
                    "sent": "So, but if you give a loading dose, you can shorten that.",
                    "label": 0
                },
                {
                    "sent": "Steady state.",
                    "label": 0
                },
                {
                    "sent": "OK, but if you look at the dosing algorithms on day four where you have and I and I, you have to measure and then check what the next dose is most patients in if you give them maintenance dose will not reach steady state, so there may not be much change in INR and therefore on day four what you were doing was actually comparing the same different arms rather than one arm where the INR may have changed another arm where the right now didn't change.",
                    "label": 0
                },
                {
                    "sent": "So what I don't know is we know from our particular trial what proportion of patients had a change in INR by default, but what I don't know is how many in COAG had a change in INR by day four, because the algorithm stretches it that they used and so the importance of the dough sing the loading dose initiation dose becomes apparent because of the half life of warfare in which which is much greater, which which is very long.",
                    "label": 1
                }
            ]
        },
        "clip_39": {
            "is_summarization_sample": true,
            "summarization_data": [
                {
                    "sent": "Also, in COAG the algorithm did not include CYP 2C9 on day one and the reason they said that I was dosing patients with start to and start three variants are lower doses during the first day of therapy may not lead to improvements.",
                    "label": 1
                },
                {
                    "sent": "Antika regulation could lead to worse antika regulation, but that statement is based on the maintenance dose.",
                    "label": 0
                },
                {
                    "sent": "That is maintenance dose that if you're patient, if you have been stable for many months, you've got a maintenance dose and and really it may not make much difference in that stage.",
                    "label": 0
                }
            ]
        },
        "clip_40": {
            "is_summarization_sample": true,
            "summarization_data": [
                {
                    "sent": "However, when we undertook a perspective course study in new starters warfrin, we found that site of Snips in CYP 2C9, but not Vico C One who associate with time to stable those time to therapeutic INR and ion are greater than four.",
                    "label": 1
                },
                {
                    "sent": "So in the algorithm that we use in EU packed, we incorporated start to and start three within the algorithm on day one.",
                    "label": 0
                },
                {
                    "sent": "But Coag didn't, and COAG only started using cytochrome P452C9 polymorphisms on day 2.",
                    "label": 0
                },
                {
                    "sent": "Day 3 on after that and that, I think may have led to differences between the two trials.",
                    "label": 0
                }
            ]
        },
        "clip_41": {
            "is_summarization_sample": true,
            "summarization_data": [
                {
                    "sent": "There was also a lot of ethnic heterogeneity in COAG, whereas in you packed it was mostly Caucasians.",
                    "label": 0
                },
                {
                    "sent": "90 centers in Caucasians in Coag 67% white, 27% black and 6% Hispanic.",
                    "label": 1
                },
                {
                    "sent": "And in COAG the Blacks did worse in the genotyped arm in then in the clinical group and there was 8% difference between the two groups and what you so you can see here is this 22C9 polymorphism frequency.",
                    "label": 0
                },
                {
                    "sent": "So start to start.",
                    "label": 0
                },
                {
                    "sent": "Three are relatively common in Caucasians, but really absent in African Americans.",
                    "label": 0
                },
                {
                    "sent": "But there's African Americans have different snip star rate Star 11 which are not found in Caucasians and So what this tells you is that if you are going to take.",
                    "label": 0
                },
                {
                    "sent": "This can algorithmics strategy.",
                    "label": 0
                },
                {
                    "sent": "You need to use ethnic specific algorithms to dose patients as well, and this is where the basic biology and knowledge of before 15 variation in different ethnic groups becomes very important.",
                    "label": 0
                }
            ]
        },
        "clip_42": {
            "is_summarization_sample": true,
            "summarization_data": [
                {
                    "sent": "Now the other thing to note was that we had different control arms and this has been used as an explanation for why things were different between the two trials.",
                    "label": 0
                },
                {
                    "sent": "In IUPAC, we used a fixed dosing regiment which reflects current clinical cares said in Sweden in the UK.",
                    "label": 1
                },
                {
                    "sent": "In COAG, a clinical algorithm was used which included all factors apart from genetics, so this was interpreted as genetics does not add anything over and above the clinical factors and some people after the trial have actually advocated the use of clinical algorithm.",
                    "label": 1
                },
                {
                    "sent": "The important thing to note here is a clinical algorithm is never been tested in randomized control trial before, so if you start incorporating clinical algorithms into clinical practice based on this trial when it's never been tested on his own compared to standard care, then you are accepting a clinical algorithm at a lower evidential standard compared to genetics.",
                    "label": 0
                },
                {
                    "sent": "And this again reflects the genetic exceptionalism that sometimes occurs and I'll come back to that.",
                    "label": 0
                },
                {
                    "sent": "However, despite the fact that we",
                    "label": 0
                }
            ]
        },
        "clip_43": {
            "is_summarization_sample": true,
            "summarization_data": [
                {
                    "sent": "Standard dosing and they had a clinical algorithm.",
                    "label": 1
                },
                {
                    "sent": "You have to look at the TTR between the two trials so you can see in COAG.",
                    "label": 1
                },
                {
                    "sent": "In the genotype Tom Percent ETR, four weeks was 45% in EU.",
                    "label": 0
                },
                {
                    "sent": "Pact is much higher at 54% in the control arm.",
                    "label": 1
                },
                {
                    "sent": "It was similar at 4 weeks and 12 weeks.",
                    "label": 1
                },
                {
                    "sent": "All the data have in the public domain is that it was 51% in both arms, but it's unlikely to be different between the genotype and control arms.",
                    "label": 0
                },
                {
                    "sent": "Yet if you look at EU pact, the TTR 67.4% in the genotype time and 63% in the control arm.",
                    "label": 0
                },
                {
                    "sent": "So what we were getting was a TTR which was much better even in the control arm compared to the genotype time at three events in COAG.",
                    "label": 0
                },
                {
                    "sent": "So despite the fact the user click algorithm their overall anticoagulation care was worse than that seen in EU pact.",
                    "label": 0
                }
            ]
        },
        "clip_44": {
            "is_summarization_sample": false,
            "summarization_data": [
                {
                    "sent": "And in fact, what you find is that we did the studies in two different countries, which are Sweden and UK.",
                    "label": 0
                },
                {
                    "sent": "And Sweden is number one in the world in terms of anticoagulation care.",
                    "label": 0
                },
                {
                    "sent": "This is data taken from reliant and you can see the current standard of antique wagon care in Sweden is the best in the world.",
                    "label": 0
                },
                {
                    "sent": "77% TTR in the UK UK is number 4 or #5 in the world with 72% so we were using two countries where the standard of anticoagulation care is very good and Despite that we were able to show.",
                    "label": 0
                },
                {
                    "sent": "Genotyped dosing algorithm actually works better in those situations.",
                    "label": 0
                }
            ]
        },
        "clip_45": {
            "is_summarization_sample": true,
            "summarization_data": [
                {
                    "sent": "And this is some unpublished data between comparing COAG and you packed, and we've what we've done here is looked at the total number of variants.",
                    "label": 1
                },
                {
                    "sent": "This includes variants in two C9 as well as variance in vitamin K. Box Art is complex, and you can categorize them as having one variant or greater than one variant.",
                    "label": 0
                },
                {
                    "sent": "And what we find is that overall in COAG there were more people with no variance compared to EU packed.",
                    "label": 0
                },
                {
                    "sent": "And we had more higher frequency of patients with at least one variant 52% compared to 36%.",
                    "label": 1
                },
                {
                    "sent": "So Becausw they had a much higher African population overall number of variants that they were actually identifying, or much less than we were in our population in our study.",
                    "label": 0
                }
            ]
        },
        "clip_46": {
            "is_summarization_sample": true,
            "summarization_data": [
                {
                    "sent": "The importance of this is perhaps seen in this slide.",
                    "label": 0
                },
                {
                    "sent": "Is that what happened with our algorithm?",
                    "label": 0
                },
                {
                    "sent": "Was it worked better if you had variance?",
                    "label": 0
                },
                {
                    "sent": "So if you didn't have any variance, you wild type for both vehicles.",
                    "label": 0
                },
                {
                    "sent": "See one ship to see nine.",
                    "label": 0
                },
                {
                    "sent": "The algorithm didn't really make much difference.",
                    "label": 0
                },
                {
                    "sent": "You can see there was no difference, only 2% difference between the genotyping control arm OK and P value was nonsignificant.",
                    "label": 0
                },
                {
                    "sent": "If you had one variant that led to 7% difference between the genotyping control arm, which is highly significant.",
                    "label": 0
                },
                {
                    "sent": "And then if you had two more variants that lead to an 11% decrease in a difference between the genotyped arm and control arm with a highly significant P value.",
                    "label": 1
                },
                {
                    "sent": "So it tells you the algorithm was particularly suitable for those who had the variance and was actually working better in those wide variants.",
                    "label": 0
                },
                {
                    "sent": "And those are the people who really need the genotype guiding our dosing algorithm.",
                    "label": 0
                },
                {
                    "sent": "If you wild type, it doesn't matter what your dosing is, doesn't matter how bad your doctors are.",
                    "label": 0
                },
                {
                    "sent": "You probably going to be alright on Warfrin.",
                    "label": 0
                },
                {
                    "sent": "In terms of our in our control, but if you do have a variant and that's at least 30% of the population that you don't need this genotype guided algorithm and data from the literature shows at 10% improvement in percent ETR.",
                    "label": 0
                },
                {
                    "sent": "And we got 11% leads to 20% improvement in clinical outcomes.",
                    "label": 1
                },
                {
                    "sent": "OK, so that's my perspective on, you know, kind of differences that occur between the Warframe you packed study and the COAG study.",
                    "label": 0
                },
                {
                    "sent": "And the next aspect for us is to start implementing that in a real world situation as well as undertakers defective.",
                    "label": 0
                }
            ]
        },
        "clip_47": {
            "is_summarization_sample": true,
            "summarization_data": [
                {
                    "sent": "Yes, the third trial that was published in the Journal of Nuclear Medicine was on the vitamin categories which are used in mainland Europe, Germany, Netherlands, Greece and so on.",
                    "label": 0
                },
                {
                    "sent": "And if you look at the literature for asynchronous recruitment, there's certainly data showing the two scenery.",
                    "label": 0
                },
                {
                    "sent": "Kosi one are very important and these investigators were able to put into seen on Vico C1 Gina types.",
                    "label": 0
                },
                {
                    "sent": "They found there's no difference in three months, but percent ETR was higher.",
                    "label": 1
                },
                {
                    "sent": "In genotype time in the first 4 weeks.",
                    "label": 1
                },
                {
                    "sent": "But what they had done is that they combined the data from a snow kumral Ann from procurement to give a total of 273 but individual individually the drugs there was only 119 Daisaku Milam and 83 in different Roku Manam.",
                    "label": 0
                },
                {
                    "sent": "So assessed individually, the trials were really very underpowered, but putting them together is when they were able to do the statistical analysis.",
                    "label": 0
                },
                {
                    "sent": "The question that you have to ask is that these drugs are completely different in terms of the pharmacology.",
                    "label": 0
                },
                {
                    "sent": "The half lives how they metabolised was it the right thing to do to combine them together?",
                    "label": 0
                }
            ]
        },
        "clip_48": {
            "is_summarization_sample": false,
            "summarization_data": [
                {
                    "sent": "And if you look at the effect of two C9 on the different enantiomers or friend procurement is no common Wolf and you can see that there are marked differences.",
                    "label": 0
                },
                {
                    "sent": "So for example, as we said, Eswar friend is a more active enantiomer and two C9 is very important here.",
                    "label": 0
                },
                {
                    "sent": "Whereas if you actually look at the Asian Okuma roll, the R 90 miles past more important and two C9 is not so important and you can see that there are three or four and etc are all involved in metabolism of these other anticoagulants.",
                    "label": 0
                },
                {
                    "sent": "And maybe more importantly, with regard to warfrin.",
                    "label": 0
                },
                {
                    "sent": "And there's also a significant amount of Enpro Kumon, which is excreted unchanged through the kidneys.",
                    "label": 0
                },
                {
                    "sent": "So therefore one would have to say that maybe combining the two pharmacologically didn't make sense, and so at the moment the jury is still out as to whether it works for Okumura Nation, Okumura.",
                    "label": 0
                }
            ]
        },
        "clip_49": {
            "is_summarization_sample": false,
            "summarization_data": [
                {
                    "sent": "So one of the other aspects that we need to contend with in clinical practice in terms of getting things into going to practice, is that there isn't a level playing field.",
                    "label": 0
                },
                {
                    "sent": "There is some genetic exceptionalism occurring and release of you know the evidence standards do differ between non genetic and genetic testing and in this particular editorial I gave examples of three different areas and I'm just going to cover drug exposure in terms of genetic except.",
                    "label": 0
                }
            ]
        },
        "clip_50": {
            "is_summarization_sample": true,
            "summarization_data": [
                {
                    "sent": "Realism, so if you have a drug which is excreted through the kidneys, and if you have a patient with kidney renal impairment, the drug label will tell you to change the dose of that drug based on the kidney impairment.",
                    "label": 0
                },
                {
                    "sent": "So here's an example, and there are many different examples like this.",
                    "label": 0
                },
                {
                    "sent": "This is a beta lactam, antibiotic aztreonam, and it says that after initial usual dosage, the dosage of aztreonam should be hard in patients with creatinine clearance between 10 to 30.",
                    "label": 1
                },
                {
                    "sent": "However, this is all based on PK, PD, modeling OK and PK studies.",
                    "label": 0
                },
                {
                    "sent": "It's not based on randomized control trial.",
                    "label": 0
                },
                {
                    "sent": "In fact it would be completely impractical to undertake a randomized control trial to implement this into clinical practice.",
                    "label": 0
                },
                {
                    "sent": "However, if I have a genetic polymorphism such as 2C9 or two, D6 etc.",
                    "label": 1
                },
                {
                    "sent": "Which leads to the same degree of change in drug exposure as renal impairment does.",
                    "label": 0
                },
                {
                    "sent": "We are often told that you need a randomized control trial.",
                    "label": 0
                },
                {
                    "sent": "We need a prospective study together into clinical practice or change the drug label.",
                    "label": 0
                },
                {
                    "sent": "Yet if you have something which is renal failure or renal impairment, you can put down to the label based on PK PD modeling.",
                    "label": 0
                },
                {
                    "sent": "So there is a degree of different evidential standards which are required for putting things into clinical practice.",
                    "label": 0
                }
            ]
        },
        "clip_51": {
            "is_summarization_sample": true,
            "summarization_data": [
                {
                    "sent": "So there may be various reasons for that.",
                    "label": 0
                },
                {
                    "sent": "There is unfamiliarity with genetic tests, people also, the physicians maybe have difficulties in interpreting the genetic tests, and also there's a perceived cost of genetic testing.",
                    "label": 1
                },
                {
                    "sent": "The cost of genetic.",
                    "label": 0
                },
                {
                    "sent": "Obviously the cost of genetic testing is coming down all the time, but I always tell the same to physicians.",
                    "label": 0
                },
                {
                    "sent": "You only do test once, once you know your jeans type, you know it.",
                    "label": 0
                },
                {
                    "sent": "You don't need to test it again, but if you want to test your renal function, you may have to do 20 times throughout your lifetime.",
                    "label": 0
                },
                {
                    "sent": "And there's 20 tests of your renal function are going to cost more than one genetic test.",
                    "label": 0
                },
                {
                    "sent": "So so you know, and that is something that needs to be cut across.",
                    "label": 1
                },
                {
                    "sent": "And there's sometimes lack of availability of tests, and I've already gone through the port and around time, but there are.",
                    "label": 0
                }
            ]
        },
        "clip_52": {
            "is_summarization_sample": false,
            "summarization_data": [
                {
                    "sent": "Things coming through in terms of guidelines.",
                    "label": 0
                },
                {
                    "sent": "For example, the European Medicines Agency had produced this guidelines, which says that you need to look at pharmacogenetic methodology's in the pharmacokinetic evaluation medicinal products and if you have a particular drug which undergoes clearance, particularly via a specific pathway which is polymorphically expressed, and then you need to undertake dosing evaluation and in the future that those evaluation may be present in new drugs at the beginning in the label so that people dosed differently and in fact.",
                    "label": 0
                },
                {
                    "sent": "Examples of this are beginning to appear.",
                    "label": 0
                },
                {
                    "sent": "Here's an example.",
                    "label": 0
                }
            ]
        },
        "clip_53": {
            "is_summarization_sample": true,
            "summarization_data": [
                {
                    "sent": "Drugs in development.",
                    "label": 0
                },
                {
                    "sent": "At the moment it's a C met inhibitor.",
                    "label": 0
                },
                {
                    "sent": "It's a selective oral, non ATP competitive small molecule inhibitors.",
                    "label": 1
                },
                {
                    "sent": "Seemeth which is being used or tested in non small cell lung cancer together in combination with alotta nib and it's metabolised by cytochrome P452C9 and what these investigators did would do actually change.",
                    "label": 0
                },
                {
                    "sent": "The dose is based on whether a patient wasn't extensive metabolizer or a poor metabolizer and you can see that in extensive metabolizers they use these kind of doses.",
                    "label": 0
                },
                {
                    "sent": "And you can see the kind of at monotherapy and with combination, the kind of air curves that they get.",
                    "label": 0
                },
                {
                    "sent": "And in two poor metabolizers they reduced the dose to 120 or 240 milligrams and you can see that the exposure is the same when you reduce the dose in those patients who are extensive metabolizers in poor metabolizers.",
                    "label": 0
                },
                {
                    "sent": "And so you're getting exact exposure, same exposure and hopefully you know getting super therapeutic exposure which leads to toxicity.",
                    "label": 0
                },
                {
                    "sent": "And clearly these drugs are toxic such as these drugs.",
                    "label": 0
                },
                {
                    "sent": "And so if you can limit exposure, you can get same efficacy but reduce toxicity and those kind of things are going to come through.",
                    "label": 0
                },
                {
                    "sent": "I think as we move forward in the future.",
                    "label": 0
                }
            ]
        },
        "clip_54": {
            "is_summarization_sample": false,
            "summarization_data": [
                {
                    "sent": "So I think just to finish off in the last few slides, I think we have to accept that response to drug even is efficacy or toxicity is a complex phenotype very similar to complex diseases?",
                    "label": 0
                },
                {
                    "sent": "And really we need to be able to undertake a systems based approaches to be able.",
                    "label": 0
                }
            ]
        },
        "clip_55": {
            "is_summarization_sample": false,
            "summarization_data": [
                {
                    "sent": "To understand that so if you consider a systems pharmacology approach, you know you will be getting a drug interacting with a particular receptor and you'll be getting the molecular changes which occur as a result of that in terms of the networks which are activated or inhibited at the cellular level and which will lead to tissue level changes in Physiology.",
                    "label": 0
                },
                {
                    "sent": "This will then lead to changes in net working within the organ system and Physiology at the level of the organ, which will then eventually lead to the whole body outcome.",
                    "label": 0
                },
                {
                    "sent": "In terms of the drug response and we really need to take all that into account in terms of really trying to define how we treat patients on an individualized basis, and in fact.",
                    "label": 0
                }
            ]
        },
        "clip_56": {
            "is_summarization_sample": true,
            "summarization_data": [
                {
                    "sent": "If we look at Warframe in a way what we have got is a very crude multiscale model.",
                    "label": 0
                },
                {
                    "sent": "We have environment where we take these into account.",
                    "label": 0
                },
                {
                    "sent": "We have pharmacokinetics which we've taken to these into account pharmacodynamics.",
                    "label": 0
                },
                {
                    "sent": "We take this into account, but what we get is about 50 to 60% prediction on the basis that where's the 40%?",
                    "label": 0
                },
                {
                    "sent": "And so this is a crude multiscale model and we need to become maybe clever.",
                    "label": 0
                },
                {
                    "sent": "And maybe the reason for the differences between the two trials.",
                    "label": 0
                },
                {
                    "sent": "Was there were differences in these particular factors which are not being taken into account.",
                    "label": 0
                },
                {
                    "sent": "For example, the environmental factors such as alcohol and smoking, or about other P-450 enzymes transcription factors.",
                    "label": 1
                },
                {
                    "sent": "What about the metabolism, particularly with respect to pharmacodynamic, determines and is at account for the missing prediction.",
                    "label": 0
                },
                {
                    "sent": "So if you take a systems approach, maybe we might get better prediction that may be important for all sorts of all sorts of.",
                    "label": 0
                },
                {
                    "sent": "Different phenotypes.",
                    "label": 0
                }
            ]
        },
        "clip_57": {
            "is_summarization_sample": true,
            "summarization_data": [
                {
                    "sent": "So, just to summarize, I think I'm in time on time.",
                    "label": 0
                },
                {
                    "sent": "Yes, that translation to clinical practice is very difficult.",
                    "label": 1
                },
                {
                    "sent": "The pathway for translation does Varian, one size does not fit all, just like pharmacogenomics.",
                    "label": 1
                },
                {
                    "sent": "One dose does not fatal.",
                    "label": 1
                },
                {
                    "sent": "Randomized control trials are certainly not the ultimate answer.",
                    "label": 1
                },
                {
                    "sent": "Translating biomarkers into clinical practice, and there is a hierarchy of evidence that people use for for translating things into practice.",
                    "label": 0
                },
                {
                    "sent": "I think randomized control trials, as you can see at the top, but we will need to use other kinds of studies, and I think systems based approaches need to be investigated, accompanied by a mechanistic analysis.",
                    "label": 0
                }
            ]
        },
        "clip_58": {
            "is_summarization_sample": false,
            "summarization_data": [
                {
                    "sent": "If you look into the future, people have suggested that this is suggestion and this might be happening in the UK that in 2019 every child born will have a whole genome sequence done at the time of birth.",
                    "label": 0
                },
                {
                    "sent": "We do a pinprick of heel prick anyway at the moment to look for inborn errors of metabolism, but maybe you could actually do whole genome sequences that time.",
                    "label": 0
                },
                {
                    "sent": "It may be cheap enough and you have that data within your electronic medical record.",
                    "label": 0
                },
                {
                    "sent": "Now, if you have that data within the electronic medical record and you know what the variants are and you have intelligent decision support systems that pops up saying that you're going to go on a 2D6 drug.",
                    "label": 0
                },
                {
                    "sent": "Are you going to ignore it or physicians going to ignore it?",
                    "label": 0
                },
                {
                    "sent": "So I think the paradigm is changing while we're acquiring randomized control trials at the moment for implementing things into clinical practice as we move forward, I think what will happen is that we will already have that data and then physicians will have to make the choice based on the advice they are given as to whether they change the dose of the drug based on the data that's already available in electronic medical record.",
                    "label": 0
                }
            ]
        },
        "clip_59": {
            "is_summarization_sample": true,
            "summarization_data": [
                {
                    "sent": "So let me just thank our various people that are involved in some of these studies and and the IUPAC group as well.",
                    "label": 0
                },
                {
                    "sent": "Here we are dealers and daily.",
                    "label": 0
                },
                {
                    "sent": "Farhad Kamalian, Kalsom, Maitland, and some of the funders that UFB 7 refunding the sort of offering study their Master drug safety Science and Wolfson Foundation funding the other cities.",
                    "label": 1
                },
                {
                    "sent": "Thank you very much for your attention.",
                    "label": 0
                },
                {
                    "sent": "Thank you for a very clear and comprehensive talk.",
                    "label": 0
                },
                {
                    "sent": "Looking at that Warframe trial and was wondering, you see that there's a benefit of the genotyping after 5 to 15 days, would you expect?",
                    "label": 0
                },
                {
                    "sent": "Already a benefit was in, for instance, the first 5 days and combined with that you looked at the time any INR in 10 weeks.",
                    "label": 0
                },
                {
                    "sent": "Should that not be shorter, so so we chose a long time interval largely to get a better perspective or what the three month over impact was, but the data I showed you was just on TTR where you were showing a different set about 10 days.",
                    "label": 0
                },
                {
                    "sent": "But there are differences at the beginning because of the high INR, so the higher now overshoot occurs within the first few days.",
                    "label": 0
                },
                {
                    "sent": "So you are seeing the difference.",
                    "label": 0
                },
                {
                    "sent": "Early on as well, in some other outcome measures, what everybody does in the literature is just focus on maintenance dose.",
                    "label": 0
                },
                {
                    "sent": "But you do need to look at other outcomes such as what the higher INR is at the beginning or the time to reach therapeutic range.",
                    "label": 0
                },
                {
                    "sent": "So if you look at the paper in the new gentleman, we've given data on all of those particular outcomes and you do get changes occurring early in other outcomes were not in TTR.",
                    "label": 0
                },
                {
                    "sent": "You'd expect the TTR to change later on because of the things that are happening with calculation factors.",
                    "label": 0
                },
                {
                    "sent": "Thank you.",
                    "label": 0
                },
                {
                    "sent": "No more questions.",
                    "label": 0
                },
                {
                    "sent": "Bully.",
                    "label": 0
                },
                {
                    "sent": "When you thanks a lot excellent talk, I wonder whether there are any data on.",
                    "label": 0
                },
                {
                    "sent": "The role of rare variants in these scenarios.",
                    "label": 0
                },
                {
                    "sent": "Do you know of any extrapolations?",
                    "label": 0
                },
                {
                    "sent": "I mean, there are data around now.",
                    "label": 0
                },
                {
                    "sent": "How many rare variants there are around and what role could they play in this?",
                    "label": 0
                },
                {
                    "sent": "And as you know, there are data on rare variants of vitamin K Books ordered this complex with respect to resistance.",
                    "label": 0
                },
                {
                    "sent": "There are some rare mutations which lead to patients requiring fifteen 2030 milligrams of warfare in a day, and those were published in nature, and we've identified some other rare variants of between cable service complaints which are unpublished, which showed that you need higher doses.",
                    "label": 0
                },
                {
                    "sent": "But there were some patients that that I saw in this trial which which really shot up even though we were using a genotype guided dosing.",
                    "label": 0
                },
                {
                    "sent": "Algorithm in them and what we're doing is sequencing the C2C9 at the moment to see whether they had any rare variants within the sub to see nine.",
                    "label": 0
                },
                {
                    "sent": "But I think there are probably going to be rare variants in the occasional patients where this algorithm will just not work, and if you look at this of all the dosing algorithms you've done, the correlation you find that at very low doses as well as the very high doses, there's very little correlation.",
                    "label": 0
                },
                {
                    "sent": "And so suggesting that there are very many other rare variants that need to be identified, particularly those extreme phenotypes.",
                    "label": 0
                },
                {
                    "sent": "No more questions please.",
                    "label": 0
                },
                {
                    "sent": "Thank you for a very interesting talk.",
                    "label": 0
                },
                {
                    "sent": "Do you think that there is enroll for cytochrome P454F2 that might explain some of the variability that you see?",
                    "label": 0
                },
                {
                    "sent": "Not really.",
                    "label": 0
                },
                {
                    "sent": "So if you look at we have got data on for F2 and so on.",
                    "label": 0
                },
                {
                    "sent": "It only accounts for about 5% of variation.",
                    "label": 0
                },
                {
                    "sent": "So even when you do sensitivity analysis of .5% between the two, it really doesn't explain it.",
                    "label": 0
                },
                {
                    "sent": "I know that the gift trial which is going on at the moment.",
                    "label": 0
                },
                {
                    "sent": "Does incorporate 4F2 but four F2 hasn't really been completely defined and and so you know because there is a huge amount of linkage disequilibrium going on across the 4F cluster with snips in four F-11, which may have an opposite effect for F2.",
                    "label": 0
                },
                {
                    "sent": "So I think 4F2 has an effect, but it's very small and the way it may have an effect may also depend on other snips in the 4F cluster which haven't been properly characterized.",
                    "label": 0
                },
                {
                    "sent": "Money I have a question.",
                    "label": 0
                },
                {
                    "sent": "Honestly saying it's really amazing to see that US trial will not consider all these limitations you mentioned, because in principle ethnicity of frequency distribution of variances is basic form genetics.",
                    "label": 0
                },
                {
                    "sent": "Why do you believe that these limitations or CS issues are not considered?",
                    "label": 0
                },
                {
                    "sent": "Before before yeah initiation of the US trial.",
                    "label": 0
                },
                {
                    "sent": "So obviously I can't answer with the US trial.",
                    "label": 0
                },
                {
                    "sent": "Nobody has seen you mentioned.",
                    "label": 0
                },
                {
                    "sent": "You should wonderful that in principle there really major limitations in terms of some.",
                    "label": 0
                },
                {
                    "sent": "Yeah, I'm issues, so there may be COAG investigators in the audience who may disagree with me and they may have their own interpretation.",
                    "label": 0
                },
                {
                    "sent": "This is my interpretation, but my feeling is that what they were trying to do was to reflect the clinical practice in the US.",
                    "label": 0
                },
                {
                    "sent": "So in the US they don't use a loading dose algorithm, so they were trying to use what the current standard is.",
                    "label": 0
                },
                {
                    "sent": "And obviously part of the population in the areas that we're looking at is much more heterogeneous in the populations that we were looking at, so that you know.",
                    "label": 0
                },
                {
                    "sent": "And it was.",
                    "label": 0
                },
                {
                    "sent": "You can't really exclude certain populations because ethnicity in taking part in trials so that that led to problems, but I guess they could have thought about changing the algorithm in those individuals and so on.",
                    "label": 0
                },
                {
                    "sent": "I guess the issue of why that include two C9 and A1, which seems a bit strange to me because a lot of the work that's been done.",
                    "label": 0
                },
                {
                    "sent": "Has been based on maintenance dose in throughout the world and that's what they focused on.",
                    "label": 0
                },
                {
                    "sent": "But actually at the beginning you don't need maintenance dose.",
                    "label": 0
                },
                {
                    "sent": "You need other parameters how high you are in Argos and so on.",
                    "label": 0
                },
                {
                    "sent": "So the algorithm at the beginning is actually different from the algorithm that you get a three months, so you know.",
                    "label": 0
                },
                {
                    "sent": "And that was part of the problem as well I think.",
                    "label": 0
                },
                {
                    "sent": "So I think focusing too much on maintenance dose leads to problems in terms of what happens at the beginning, which is what the difference was between the two trials between day and 1.",
                    "label": 0
                },
                {
                    "sent": "Three.",
                    "label": 0
                },
                {
                    "sent": "OK. No more questions.",
                    "label": 0
                },
                {
                    "sent": "The only one coming but are currently the current practice in UK.",
                    "label": 0
                },
                {
                    "sent": "Do you use for testing buffering algorithm for clinical practice?",
                    "label": 0
                },
                {
                    "sent": "So at the moment the standard practices that we give a loading those 10, five, 5 or 1010 five depending which hospital you're in?",
                    "label": 0
                },
                {
                    "sent": "If you're elderly, you give 555 for the first days.",
                    "label": 0
                },
                {
                    "sent": "There's no genetic testing going on at the moment, but what we're about to start is an implementation study in some real world practices in the Community with general practices whereby they're going to Geno type in a real world setting and then compare that to other studies to see whether it works in real world setting.",
                    "label": 0
                },
                {
                    "sent": "Not randomized, just everybody coming to the clinic, and so if we can do that kind of implementation and show it works and do the cost effectiveness around it, then we can actually start putting things into guidelines and so on, OK?",
                    "label": 0
                },
                {
                    "sent": "Dope moon yeah thank you so much for your talking to this introduction pharmacogenomics today, so and now.",
                    "label": 0
                },
                {
                    "sent": "It's time for coffee.",
                    "label": 0
                }
            ]
        }
    }
}